Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults by Walsh, Tanya et al.
                                                              
University of Dundee
Clinical assessment to screen for the detection of oral cavity cancer and potentially
malignant disorders in apparently healthy adults
Walsh, Tanya; Liu, Joseph L. Y.; Brocklehurst, Paul; Glenny, Anne-Marie; Lingen, Mark; Kerr,
Alexander R.; Ogden, Graham; Warnakulasuriya, Saman; Scully, Crispian
Published in:
Cochrane Database of Systematic Reviews
DOI:
10.1002/14651858.CD010173.pub2
Publication date:
2013
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Walsh, T., Liu, J. L. Y., Brocklehurst, P., Glenny, A-M., Lingen, M., Kerr, A. R., ... Scully, C. (2013). Clinical
assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently
healthy adults. Cochrane Database of Systematic Reviews, 2013(11), 1-70. [CD010173].
https://doi.org/10.1002/14651858.CD010173.pub2
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Cochrane Database of Systematic Reviews
Clinical assessment to screen for the detection of oral cavity
cancer and potentially malignant disorders in apparently
healthy adults (Review)
Walsh T, Liu JLY, Brocklehurst P, Glenny AM, Lingen M, Kerr AR, Ogden G, Warnakulasuriya S,
Scully C
Walsh T, Liu JLY, Brocklehurst P, Glenny AM, Lingen M, Kerr AR, Ogden G, Warnakulasuriya S, Scully C.
Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults.
Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010173.
DOI: 10.1002/14651858.CD010173.pub2.
www.cochranelibrary.com
Clinical assessment to screen for the detection of oral cavity cancer and potentiallymalignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
9RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
17DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
59DATA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Test 1. Conventional oral examination. . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Test 2. Mouth self examination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
60ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
69DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
70INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iClinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Diagnostic Test Accuracy Review]
Clinical assessment to screen for the detection of oral cavity
cancer and potentially malignant disorders in apparently
healthy adults
Tanya Walsh1, Joseph LY Liu2, Paul Brocklehurst1, Anne-Marie Glenny3, Mark Lingen4, Alexander R Kerr5, Graham Ogden6, Saman
Warnakulasuriya7 , Crispian Scully8
1School of Dentistry, The University of Manchester, Manchester, UK. 2University of Dundee, Dental Health Services Research Unit,
Scottish Dental Clinical Effectiveness Programme, NHS Education for Scotland, Dundee, UK. 3Cochrane Oral Health Group, School
ofDentistry, TheUniversity ofManchester,Manchester, UK. 4Pritzker School ofMedicine,Division of Biological Sciences, Department
of Pathology, University of Chicago, Chicago, Illinois, USA. 5Department ofOral andMaxillofacial Pathology, Radiology andMedicine,
New York University College of Dentistry, New York, USA. 6Division of Oral and Maxillofacial Clinical Sciences, School of Dentistry,
University of Dundee, Dundee, UK. 7Clinical and Diagnostic Sciences, King’s College London, London, UK. 8University College
London, London, UK
Contact address: Tanya Walsh, School of Dentistry, The University of Manchester, Coupland III Building, Oxford Road, Manchester,
M13 9PL, UK. tanya.walsh@manchester.ac.uk.
Editorial group: Cochrane Oral Health Group.
Publication status and date: New, published in Issue 11, 2013.
Review content assessed as up-to-date: .
Citation: Walsh T, Liu JLY, Brocklehurst P, Glenny AM, Lingen M, Kerr AR, Ogden G, Warnakulasuriya S, Scully C. Clinical
assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane
Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010173. DOI: 10.1002/14651858.CD010173.pub2.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
The early detection and excision of potentially malignant disorders (PMD) of the lip and oral cavity that require intervention may reduce
malignant transformations (though will not totally eliminate malignancy occurring), or if malignancy is detected during surveillance,
there is some evidence that appropriate treatment may improve survival rates.
Objectives
To estimate the diagnostic accuracy of conventional oral examination (COE), vital rinsing, light-based detection, biomarkers and
mouth self examination (MSE), used singly or in combination, for the early detection of PMD or cancer of the lip and oral cavity in
apparently healthy adults.
Search methods
We searched MEDLINE (OVID) (1946 to April 2013) and four other electronic databases (the Cochrane Diagnostic Test Accuracy
Studies Register, the Cochrane Oral Health Group’s Trials Register, EMBASE (OVID), and MEDION) from inception to April 2013.
The electronic databases were searched on 30 April 2013. There were no restrictions on language in the searches of the electronic
databases. We conducted citation searches, and screened reference lists of included studies for additional references.
Selection criteria
We selected studies that reported the diagnostic test accuracy of any of the aforementioned tests in detecting PMD or cancer of the lip
or oral cavity. Diagnosis of PMD or cancer was made by specialist clinicians or pathologists, or alternatively through follow-up.
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Data collection and analysis
Two review authors independently screened titles and abstracts for relevance. Eligibility, data extraction and quality assessment were
carried out by at least two authors independently and in duplicate. Studies were assessed for methodological quality using QUADAS-
2. We reported the sensitivity and specificity of the included studies.
Main results
Thirteen studies, recruiting 68,362 participants, were included. These studies evaluated the diagnostic accuracy of COE (10 studies),
MSE (two studies). One randomised controlled of test accuracy trial directly evaluated COE and vital rinsing. There were no eligible
diagnostic accuracy studies evaluating light-based detection or blood or salivary sample analysis (which tests for the presence of bio-
markers of PMD and oral cancer). Given the clinical heterogeneity of the included studies in terms of the participants recruited, setting,
prevalence of target condition, the application of the index test and reference standard and the flow and timing of the process, the data
could not be pooled. For COE (10 studies, 25,568 participants), prevalence in the diagnostic test accuracy sample ranged from 1% to
51%. For the eight studies with prevalence of 10% or lower, the sensitivity estimates were highly variable, and ranged from 0.50 (95%
confidence interval (CI) 0.07 to 0.93) to 0.99 (95% CI 0.97 to 1.00) with uniform specificity estimates around 0.98 (95% CI 0.97
to 1.00). Estimates of sensitivity and specificity were 0.95 (95% CI 0.92 to 0.97) and 0.81 (95% CI 0.79 to 0.83) for one study with
prevalence of 22% and 0.97 (95% CI 0.96 to 0.98) and 0.75 (95% CI 0.73 to 0.77) for one study with prevalence of 51%. Three
studies were judged to be at low risk of bias overall; two were judged to be at high risk of bias resulting from the flow and timing
domain; and for five studies the overall risk of bias was judged as unclear resulting from insufficient information to form a judgement
for at least one of the four quality assessment domains. Applicability was of low concern overall for two studies; high concern overall
for three studies due to high risk population, and unclear overall applicability for five studies. Estimates of sensitivity for MSE (two
studies, 34,819 participants) were 0.18 (95% CI 0.13 to 0.24) and 0.33 (95% CI 0.10 to 0.65); specificity for MSE was 1.00 (95%
CI 1.00 to 1.00) and 0.54 (95% CI 0.37 to 0.69). One study (7975 participants) directly compared COE with COE plus vital rinsing
in a randomised controlled trial. This study found a higher detection rate for oral cavity cancer in the conventional oral examination
plus vital rinsing adjunct trial arm.
Authors’ conclusions
The prevalence of the target condition both between and within index tests varied considerably. For COE estimates of sensitivity over
the range of prevalence levels varied widely. Observed estimates of specificity were more homogeneous. Index tests at a prevalence
reported in the population (between 1% and 5%) were better at correctly classifying the absence of PMD or oral cavity cancer in
disease-free individuals that classifying the presence in diseased individuals. Incorrectly classifying disease-free individuals as having
the disease would have clinical and financial implications following inappropriate referral; incorrectly classifying individuals with the
disease as disease-free will mean PMD or oral cavity cancer will only be diagnosed later when the disease will be more severe. General
dental practitioners and dental care professionals should remain vigilant for signs of PMD and oral cancer whilst performing routine
oral examinations in practice.
P L A I N L A N G U A G E S U M M A R Y
The detection of oral cavity cancers and potentially malignant disorders in apparently healthy adults
Cancer of the mouth is a serious condition and only half of those that develop the disease manage to survive after five years. It is
commonly preceded by visible lesions, which if identified early, can be treated and could result in simpler surgery and much better
outcomes. As a result, there is a need to understand how good different types of tests are at the early detection of oral cancer and the
lesions that precede it. The most common method is an oral visual inspection by a clinician, but other tests include the use of a blue
’dye’, illumination with a special light and self examination by the individual. The review found a lot of variety in the ability of the
different tests to differentiate between healthy mouths and non-referable lesions and more serious lesions or oral cancer. Overall, visual
examination by a front-line health worker proved to be the best method. Between 59% and 99% of mouth cancers were detected,
although sometimes normal tissue was mistaken for oral cancer. The remaining techniques examined were not as good at detecting
mouth cancer and identified less than a third of cases.
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B A C K G R O U N D
Target condition being diagnosed
The target conditions of interest are oral cavity cancer and po-
tentially malignant disorders (PMD) of the lip and oral cavity.
PMD is a term used to describe a range of lesions that present in
the mouth and have the potential for malignant transformation.
These include: erythroplakia, non-homogeneous leukoplakia, ero-
sive lichen planus, oral submucous fibrosis and actinic keratosis
(van der Waal 2009; Warnakulasuriya 2007).
The natural history of oral cancer is not fully understood (Napier
2008; Scully 2009). Carcinogenesis is a complex disease pro-
cess; not all oral cancers will be preceded by PMD and not all
PMD undergoes malignant transformation. Erythroplakia, non-
homogeneous leukoplakia, erosive lichen planus, oral submu-
cous fibrosis and actinic keratosis are the most important PMDs
(Warnakulasuriya 2007) to proceed to carcinoma. Oral leuko-
plakia is the most common form of PMD and is defined as
“white plaques of questionable risk having excluded (other) known
diseases or disorders that carry no increased risk for cancer”
(Warnakulasuriya 2007). Between < 1% and 18% of oral leuko-
plakias undergo malignant transformation. The presence of ep-
ithelial dysplasia can help predict malignant development in oral
leukoplakia but the process is not linear; some mild dysplastic le-
sions undergo malignant transformation, whilst some severe le-
sions resolve (Jaber 2003; Reibel 2003). Carcinoma can also de-
velop from lesions in which epithelial dysplasia was not previously
diagnosed (Jaber 2003; Reibel 2003). As a result, most authorities
regard leukoplakia as a dynamic rather than a static process (Napier
2008). In contrast, PMDs that are red or predominantly red in
colour (e.g. erythroplakia and erythroleukoplakias) undergo ma-
lignant transformation more readily (Mashberg 1988; Mashberg
1995; Scully 2009).
Estimates of malignant transformation rates (MTR) vary enor-
mously, from site to site within the mouth, from population to
population and from study to study (Napier 2008). The MTR of
hospital-based surveys are consistently higher than community-
based studies because of sampling bias. Petti 2003 calculated a
global MTR of oral leukoplakia of 1.36% per year (95% confi-
dence interval (CI) 0.69% to 2.03%) based on the prevalence of
oral leukoplakia, but this far exceeds the numbers of actual cases of
malignancy. Virtually all studies emphasize the chronicity of oral
PMD,with an increasing tendency tomalignant change in the first
five years. For example, the incidence of oral squamous cell carci-
noma (OSCC) arising from leukoplakia in Californians was great-
est in the second year of follow-up (11 out of 45; 24%) (Silverman
1984). The proportion of PMD that will develop OSCC is un-
certain but low; best estimates suggest a rate of less than 2% per
annum (Napier 2008).
The early detection and management of potentially malignant
disorders of the lip and oral cavity that require intervention may
reduce malignant transformations (though will not totally elim-
inate malignancy occurring), or if malignancy is detected dur-
ing surveillance, there is some evidence that appropriate treat-
mentmay improve survival rates (Brocklehurst 2010; van derWaal
2009; Warnakulasuriya 2007). However, Lodi 2006 investigated
the effectiveness of different management strategies for oral leuko-
plakia and found a lack of evidence for surgical interventions, in-
cluding laser therapy and cryotherapy. Vitamin A, retinoids, beta
carotene, carotenoids, bleomycin, mixed tea and ketorolac have
also been tried, but none of the treatments tested showed a benefit
when compared with the placebo. Lodi et al concluded that there
was no evidence of effective treatment in preventing themalignant
transformation of leukoplakia (Lodi 2006). There is also debate in
the literature about the impact “field change” (Holmstrup 2006;
Holmstrup 2009). Holmstrup argues that even if early lesions are
surgically removed, the risk of malignant change can remain as
a result of the lesion representing a small area of a wider field of
damaged mucosa (Holmstrup 2006; Holmstrup 2009).
Technologies to treat and manage oral cancer have progressed sub-
stantially, as shownby systematic reviews of randomised controlled
trials of interventions (e.g. Bessell 2011; Furness 2011; Glenny
2010). Once frank malignancy has been detected, the traditional
management of oral cancer is through surgery and radiotherapy.
More recently, systemic chemotherapy has been included as part
of the treatment regimen before or during radiotherapy. Surgery
for the treatment of oral cancer is followed by exacting recon-
structive surgery to restore form and function. Debilitating side
effects can occur as a result of both the surgery and radiother-
apy and chemotherapy, adversely affecting an individual’s quality
of life. The five-year survival following diagnosis has remained at
around 50% for the past 30 years in most countries (Parkin 2001;
Warnakulasuriya 2009). Recent US data show a statistically sig-
nificant improvement among patients treated for oral squamous
cell carcinoma from 55% in 1984 to 1986 to 60% in the 1996
to 2003 time frame (Jemal 2008). This is in marked contrast to
the improved survival rates in many other cancers, such as those
of the breast and the colon (Cancer Research UK), but may be
explained at least in some part by the fact that oral cancer is more
often diagnosed at a late stage of the disease, when prognosis is
poorer and the risks of significant morbidity and mortality are
substantially higher (Rogers 2009; Rusthoven 2010).
Index test(s)
Reviews of primary studies of diagnostic test accuracy in this area
have identified a number of index tests which could be used as
adjuncts to the conventional visual and tactile oral examination
(COE) to improve earlier detection of lip and oral cavity cancer
and PMD (Fedele 2009; Leston 2010; Lingen 2008; Patton 2008;
Rethman 2010). These include:
• vital rinsing or staining (Toluidine blue, Tolonium chloride)
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• light-based detection (such as ViziLite and ViziLite Plus,
Microlux/DL, VELscope, Orascoptic DK, Identafi 3000)
• mouth self examination
• blood and saliva analyses.
Vital rinsing and oral cytology are long available adjuncts to a con-
ventional oral examination (Leston 2010; Lingen 2008). Other
tests such as light-based detection systems have become commer-
cially available only more recently. Mouth self examination is a
simple technique with world wide application. Blood analysis and
saliva analysis are more novel tests at an early stage of evaluation.
It is worth noting that for an index test to obtain the US Food
and Drug Administration (FDA) ’clearance’ (the term reserved for
non-invasive devices) a demonstration of efficacy is not required,
only a demonstration of safety.
Of the index tests listed above, vital rinsing, light-based detec-
tion, mouth self examination and blood and saliva analyses could
be used as screening adjuncts to the COE (Additional Table 1).
Where access to general dental practitioners or general medical
practitioners is limited, either as a result of geographical location or
barriers to uptake of healthcare provision, screening using the in-
dex tests listed above could, in principle, be undertaken by trained
healthcare workers; all have the potential to be used as adjuncts to
the COE by healthcare workers or clinicians undertaking screen-
ing of the general population. Adding any one of the proposed
index tests to the COE, the tests could have a triage role in detect-
ing lesions of uncertain significance with referral where appropri-
ate. For instance, traumatic keratoses are common, and referring
each patient with a white patch to a specialist to undergo a scalpel
biopsy is excessive, and incurs increased financial cost and patient
worry, and potentially delays the more urgent referrals being seen.
A non-invasive index test or combination of tests adjunctive to
the COE that provides a frontline clinician with a high degree of
accuracy would not only reduce the number of patients with be-
nign disease being referred, but could avoid the need for invasive
biopsy in patients testing negative.
A companion Cochrane systematic review evaluates the diagnostic
accuracy of index tests in individuals presenting with clinically
evident lesions (Liu 2012).
Clinical pathway
The standard process of screening apparently healthy adults for
PMD and cancer of the lip or oral cavity is by a systematic and
thorough visual inspection of the oral mucosa and palpation of
the neck under normal (incandescent) light for lymphadenopa-
thy. In most instances this is carried out by a frontline clinician
opportunistically as part of a routine recall examination by a den-
tist. This conventional visual and tactile oral examination (COE)
used can be conducted with the minimum of effort and distress
to the individual (Additional Table 1). Screening can be carried
out opportunistically, for instance when an individual presents to
their dentist for a check-up, or as part of an organised screening
programme. The COE is usually followed by referral for further
investigation if this is deemed necessary. The form that further in-
vestigation takes is variable nationally and internationally; it could
be an examination/biopsy by a specialist in oral medicine or oral
surgery at a secondary or tertiary clinic.
Rationale
Oral cancer is a significant global health problem with increas-
ing incidence and mortality rates (Ferlay 2010; Warnakulasuriya
2009). Cancer of the lip or oral cavity is a relatively common can-
cer worldwide, with an estimated 263,000 new cases and 127,000
deaths in 2008, and an increasing incidence in recent years (Ferlay
2010). There is wide geographic variation in disease incidence and
mortality, with almost double the incidence in low-income and
middle-income countries as in high-income countries, and a three-
fold increase in mortality. Tobacco use, alcohol consumption, be-
tel quid chewing and low socio-economic status have traditionally
been thought to be the most important risk factors of oral can-
cer (Conway 2008; Faggiano 1997; La Vecchia 1997; Macfarlane
1995; Ogden 2005). Men have had a higher incidence of oral
cancer than women (Ferlay 2010), but this disparity can be ex-
plained by men having a higher exposure to the above risk factors
(Freedman 2007). The gender difference has narrowed in recent
decades from a ratio of five males to one female diagnosed with
oral cancers in the 1960s to less than two to one in 2008 (Ferlay
2010). Although traditionally the risk of oral cancer increases with
age, the incidence among younger adults has been increasing in the
European Union and the United States (Warnakulasuriya 2009).
In the United Kingdom, one in 10 cases are now below the age of
45 years (Cancer ResearchUK).The five-year survival rate depends
on multiple factors, including patient and tumour characteristics,
treatment received and stage at diagnosis. Oral cancer incidence
and mortality can be reduced using three approaches: (i) primary
prevention, (ii) secondary prevention, screening and early detec-
tion, and (iii) improved treatment (Scully 2000b).
Successful early detection of oral cavity cancer or PMD is highly
dependent on whether individuals with the disease present for a
screen. Early detection relies on the awareness and motivation of
the clinician or patient in identifying a suspicious lesion or symp-
tom while it is still at an early stage. Whilst many organisations
advocate cancer-related checks, including the American Cancer
Society for individuals of all risk groups (American Cancer Society
1992) and the US Preventive Health Services Task Force for high
risk individuals (US Preventive Services Task Force in discussion),
there is much global variation in the provision and promotion of
routine oral cancer examinations. Currently, no national popula-
tion-based screening programmes for oral cancer have been im-
plemented in the high-income countries, although opportunistic
screening has been advocated (Brocklehurst 2013). Consequently,
individuals will often present for examination at a later stage of the
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disease, when the risks of significant morbidity and mortality are
substantially higher. The British Columbia Oral Cancer Preven-
tion Program (BC OCPP) is addressing this challenge in several
ways: by linking community dental practices and referral centres,
by creating partnerships between scientists and clinicians that al-
ready have resulted in new technologies to enhance early diagno-
sis, by involving a broad range of stakeholders to ensure popula-
tion-based screening and by engaging in provincial, national and
international outreach (Rosin 2006). Brocklehurst et al’s system-
atic review identified only one randomised controlled trial using
visual examination with a follow-up period of 15 years which was
carried out in India. The authors of the review concluded that op-
portunistic screening of high risk groups may potentially improve
outcomes, although the risk of bias of the included study was high
(Brocklehurst 2013).
There is some debate in the literature on anticipated differences in
diagnostic accuracy of prospective population-based invitational
screening programmes and a more opportunistic approach (when
patients attend their general (dental) practitioner for routine ex-
amination or for treatment). In Downer et al’s systematic review
of test performance in screening for oral cancer and PMD, only
prospective investigations of population screening with specified
reference standards were included. The pooled sensitivities and
specificities were 0.85 (95% CI 0.730 to 0.919) and 0.97 (95%
CI 0.930 to 0.982) respectively (Downer 2004). An opportunistic
approach that focuses on high risk groups is also possible (McGurk
2010; Sankaranarayanan 1997). A simulation study which used
neural network and machine learning techniques suggested op-
portunistic screening aimed at high risk groups may be both ef-
fective and cost-effective (Speight 2006). However, many individ-
uals with risk factors may not attend the dentist and are therefore
not amenable to an opportunistic approach (Netuveli 2006; Yusof
2006).
Reviews assessing the test accuracy of a conventional oral exami-
nation as a population screening tool (e.g. Downer 2004; Moles
2002) have highlighted methodological flaws in the primary di-
agnostic test accuracy studies, although explicit methodological
quality assessment of these studies using a validated and widely
used checklist was not undertaken.
In this review we have identified screening tests for PMD and
cancer of the lip or oral cavity to evaluate the diagnostic accuracy
of the COE and the accuracy of the other index tests (Additional
Table 1) used as adjuncts to the oral examination in asymptomatic
adults. The index tests proposed for evaluation in this review are
suitable for use in the community or as part of a dental examination
in a general dental practitioners’ office. The review includes both
prospective investigations of organised screening programmes and
prospective opportunistic screening. It is important that this re-
view considered both as individuals screened opportunistically are
self selecting and may not be representative of the population of
interest. In either scenario, screening may be carried out by dental
professionals or healthcare workers. The purpose of the screening
is to identify the presence or absence of PMD which require re-
ferral to secondary care for definitive diagnosis and possibly treat-
ment. The proposed index tests cannot confirm whether a PMD
is cancerous before deciding on referral to secondary care; biopsy
with histopathology is currently the only confirmatory method of
oral cancer diagnosis.
The Cochrane Oral Health Group has undertaken a number of
intervention reviews in the field of treatment of oral and oropha-
ryngeal cancers (Bessell 2011; Furness 2011; Glenny 2010) and
screening programmes for the early detection and prevention of
oral cancer (Brocklehurst 2013). This screening test accuracy re-
view complements the intervention reviews.
O B J E C T I V E S
To estimate the diagnostic accuracy of conventional oral examina-
tion (COE), vital rinsing, light-based detection, biomarkers and
mouth self examination (MSE), used singly or in combination,
for the early detection of potentially malignant disorders (PMD)
or cancer of the lip and oral cavity in apparently healthy adults.
Secondary objectives
To estimate the accuracy of the different index tests with COE,
when compared with each other.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies of cohorts of apparently healthy adults which
evaluated the diagnostic accuracy of the conventional oral exam-
ination (COE) used singly or in combination with an index test
listed in Additional Table 1, in screening for potentially malig-
nant disorders (PMD) and cancer of the lip or oral cavity. These
included cross-sectional studies (or consecutive series) and ran-
domised controlled trials (RCTs) of test accuracy. We excluded
case series and case-control studies which could lead to inflated
estimates of prevalence and test accuracy (Whiting 2004).We also
excluded studies reported in abstract form alone, uncontrolled
reports and randomised controlled trials of the effectiveness of
screening programmes (intervention studies). Where randomised
or paired comparative designs were available these were included
in the review and analysed separately. Only studies reporting data
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for true positives, false positives, true negatives and false negatives
at an individual level (as opposed to a lesion level) for each test
were included. No language restrictions were imposed.
Participants
Apparently healthy adults not reporting symptoms attending an
organised screening programme or screened during attendance at
a dental or other clinical practice examination. We did not exclude
specific subgroups of patients in this review, such as high risk
cohorts or cohorts with previous suspicions on PMD or cancer of
the lip or oral cavity.
Index tests
TheCOE used as a screen, alone or in combination with any other
screening tests previously listed (Additional Table 1). The COE
(conventional testing test) was the initial point of the screen, which
all individuals received. The index test was used as an adjunct
following the COE irrespective of whether oral cancer or PMD
was suspected by the COE alone (i.e. a positive test result is a
positive result from either the COE or the index test or both).
Target conditions
Following the consensus views of the expert working group of
theWorldHealthOrganization (WHO)Collaborating Center for
Oral Cancer and Precancer, the target conditions of the lip or oral
cavity of interest are noted as.
- Carcinoma of the lip or oral cavity.
- Potentially malignant disorders.
• Leukoplakia.
• Erythroplakia.
• Lichen planus.
• Lupus erythematosus.
• Submucous fibrosis.
• Actinic keratosis.
• Hereditary disorders such as dyskeratosis congenita or
epidermolysis bullosa.
Reference standards
The reference standard was examination and clinical evaluation
by a physician with specialist knowledge or training, working to
the current diagnostic guidelines of their locality. At the most ex-
perienced level this would be an oral and maxillofacial patholo-
gist or oral medicine specialist possibly utilising biopsy with his-
tology where considered clinically appropriate. More commonly
this was expected to include general dental physicians in receipt
of supplementary training in the detection and identification of
PMD and carcinoma of the lip or oral cavity or other physicians
with dedicated training. We included studies where confirmation
of individuals screened negative by the index test was done by ex-
tended follow-up. To be eligible for inclusion in the review, at least
a proportion of the screened negatives were required to be verified.
Where reported, for each study we noted the diagnostic protocol,
guidelines or registry used for follow-up in the Characteristics of
included studies table. Studies with confirmatory biopsy of indi-
viduals who screened negative by the index test were eligible for
inclusion although ethically questionable (Downer 2004).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases.
• The Cochrane Diagnostic Test Accuracy Studies Register
(to 30 April 2013).
• The Cochrane Oral Health Group’s Trials Register (to 30
April 2013).
• MEDLINE via OVID (1946 to 30 April 2013).
• EMBASE via OVID (1980 to 30 April 2013).
• MEDION (2003 to 30 April 2013).
See Appendix 1 for the search strategies used. There were no re-
strictrions on language in the searches of the electronic databases.
We constructed the electronic search strategy in accordance with
this review and that of a companion Cochrane diagnostic test
accuracy review (Liu 2012) which was undertaken concurrently
by the same review team.
Searching other resources
We sought to locate further studies through citation searches and
reference lists of key articles, and by contacting authors of identi-
fied articles to request information of any unpublished or ongoing
studies.
Data collection and analysis
Selection of studies
We did not limit the screening of the search results by publication
language or status. Non-English articles were translated. Titles and
abstracts of all articles identified from the searches were indepen-
dently assessed by two review authors. For articles appearing to
meet the inclusion criteria, or where a clear decision was unable
to be made from scanning the title and abstract alone, full reports
were obtained. Where disagreements occurred, these were resolved
by discussion with the review team.
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Data extraction and management
Two review authors independently extracted data using a piloted
data collection form. Discrepancies were resolved through discus-
sion with the review team. Study authors were contacted to ob-
tain relevant missing data if these were not available in the printed
report.
From each study, we extracted the following data.
• Sample characteristics (age, sex, socio-economic status, risk
factors (e.g. human papillomavirus (HPV) status, prevalence of
tobacco use and alcohol consumption), number of participants/
lesions).
• Setting (country, disease prevalence, type of screening).
• Type of index test(s) (category, name, positivity threshold).
• Study information (design, reference standard, case
definition, training and calibration of personnel).
• Study results (true positive, true negative, false positive,
false negative, any equivocal results, withdrawal or exclusions).
This information was documented in the Characteristics of
included studies table for each study.
Assessment of methodological quality
Weused theQUADAS-2 tool (Whiting 2011) to assess the quality
of the included studies over four key domains: patient selection,
index test, reference standard and flow and timing of participants
through the study. The QUADAS-2 tool was tailored specifically
for this review (Additional Table 2). Review specific guidance was
used to facilitate documentation of the pertinent descriptive in-
formation contained in the studies. Customised instructions to
aid judgement of the signalling questions were given (following
Patton 2008). Two core signalling questions were removed: ’Was a
case-control design avoided?’ (this study design was excluded from
the review); ’Did all patients receive a reference standard?’ (this
was a criterion for inclusion). Two additional signalling items re-
lating to commercial funding and multiple index tests were added
to the core signalling questions. Responses to the signalling ques-
tions, risk of bias and applicability judgements are presented in the
Characteristics of included studies tables and summarised graph-
ically (Figure 1).
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Figure 1. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Statistical analysis and data synthesis
Data for the true positive, true negative, false positive and false
negative values for each test in each study was entered into Review
Manager (RevMan 2012). For each index test, estimates of the
diagnostic accuracy were expressed as sensitivity and specificity
with 95% confidence intervals. This information was displayed as
coupled forest plots (Figure 2), and plotted in receiver operating
characteristic (ROC) space.
Figure 2. Forest plot of 1. Conventional oral examination.
For the primary analysis we had intended to undertake a meta-
analysis to combine the results of the studies for each index test.
However, the substantial diversity of characteristics of the included
studies meant that this was not appropriate.
We were only able to include one study (Su 2010) that directly
evaluated the comparative accuracy of more than one index test
with the reference standard, i.e. randomising individuals to differ-
ent index tests. This study was reported separately.
Investigations of heterogeneity
We planned to explore possible sources of heterogeneity through
meta-regression including the following covariates: characteristics
of the study sample (prevalence of carcinoma or PMD in the
study (> 50% prevalence); inclusion of HPV + adults; tobacco
users/high alcohol consumption); target condition (oral squamous
cell carcinoma alone or oral squamous cell carcinoma and PMD);
aspects of study design (prospective organised or opportunistic);
type of reference standard (examination and clinical evaluation by
physician with specialist knowledge or extended follow-up) and
operator (dental or general medical practice professionals or other
healthcare workers). Given the diversity of the studies this was not
undertaken.
Sensitivity analyses
No sensitivity analyses were undertaken.
Assessment of reporting bias
Tests for reporting bias were not conducted because current tests
are misleading when applied to systematic reviews of diagnostic
test accuracy (Leeflang 2008).
R E S U L T S
Results of the search
After de-duplication the initial electronic search conducted in
April 2013 retrieved 4220 records.These were screened indepen-
dently and in duplicate according to eligibility criteria; 33 records
were considered potentially eligible for inclusion. Of this number,
17 records with 13 studies were included in the review. The main
reasons for exclusion were ineligible study design or no reference
standard data for individuals screened negative. Ten studies re-
ported on the diagnostic accuracy of conventional oral examina-
tion (COE) alone; two studies reported on mouth self examina-
tion and one randomised controlled trial directly compared COE
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alone with COE plus a vital rinsing agent (Toluidine blue). No
diagnostic test accuracy studies meeting the review inclusion cri-
teria evaluating any other pre-specified index test were found.
Four studies are still awaiting classification and one is ongoing.
Methodological quality of included studies
The assessment of methodological quality is presented graphically
in Figure 1.
Conventional oral examination
The nature of the screening of participants can be broadly cate-
gorized into opportunistic screening (Chang 2011; Julien 1995),
organised screening programmes (Downer 1995; Jullien 1995a;
Warnakulasuriya 1990; Warnakulasuriya 1991), validation as part
of an organised screening programme or randomised controlled
trial (Ikeda 1995; Mathew 1997; Mehta 1986) and screening as
part of a routine surveillance appointment (Sweeny 2011).
The accuracy of detecting potentiallymalignant disorders (PMDs)
and oral cavity cancer was evaluated in a variety of different
settings: In Tokoname, Japan, all residents of 60 years of age
were invited by mail to attend a dental screening programme
at a health centre (Ikeda 1995). In Kerala, India, basic health-
care workers incorporated screening into their routine house visits
(Mathew 1997; Mehta 1986) as in Sri Lanka (Warnakulasuriya
1990; Warnakulasuriya 1991). In the United Kingdom, the fea-
sibility and accuracy of workplace screening was evaluated in one
study (Downer 1995), of screening patients at a medical practice
in another (Julien 1995a), and opportunistically in patients at-
tending a dental hospital for an out-patient appointment (Julien
1995). In Taiwan, screening was offered to individuals attending
a tertiary referral centre (Chang 2011). In the USA, screening was
part of the routine surveillance visit of patients attending an oto-
laryngology clinic (Sweeny 2011).
Risk of bias for the patient selection domain was low for all stud-
ies with one exception (Julien 1995). This study was judged as
unclear as the method of patient selection for this opportunistic
screening study was not reported. Two studies were judged to be
of low concern for applicability (Julien 1995; Julien 1995a); five
studies of unclear applicability as a result of not fully reporting the
participant characteristics or risk factors of the study sample or
both (Downer 1995; Ikeda 1995;Mathew 1997;Warnakulasuriya
1990; Warnakulasuriya 1991). Three studies were selective in
their sampling, targeting a ’high risk’ population. These were all
male patients attending the otolaryngology or dental department
(Chang 2011), previous cancer patients attending the otolaryn-
gology clinic for a routine surveillance visit (Sweeny 2011) and in-
dividuals over 35 years of age with “tobacco habits” (Mehta 1986).
The COE index test was carried out by clinicians (general dental
practitioners, community dental officers, otolaryngologists) in six
studies (Chang 2011; Downer 1995; Ikeda 1995; Julien 1995;
Julien 1995a; Sweeny2011) and by health workers in the studies in
India andSri Lanka (Mathew 1997;Mehta1986;Warnakulasuriya
1990; Warnakulasuriya 1991). The risk of bias judgements for
this domain were judged to be low in nine studies. The index test
was carried out prior to the reference standard and a positivity
threshold for the target condition was specified a priori. One study
(Sweeny 2011) was judged to be at unclear risk of bias as there was
a lack of clear definition of the target condition and the positivity
threshold. All studies were judged to be at low concern regarding
applicability.
Four studies (Downer 1995; Ikeda 1995; Julien 1995; Julien
1995a) were judged to be at low risk of bias for the reference stan-
dard domain. In these studies the reference standard was carried
out by experienced specialist physicians and the results were inter-
preted without knowledge of the results of the index tests. For the
remaining studies it was unclear whether the reference standard
personnel were unaware of the results of the index test when in-
terpreting the reference standard. One study (Sweeny 2011) was
judged to be at unclear concern regarding applicability as the tar-
get definition was recurrence of head and neck cancer; all other
studies were judged as low concern.
For the flow and timing domain, two studies were judged to be
at high risk of bias as a result of attrition following positive screen
(37.5% of screen positive) and differential verification (Chang
2011) and time from screenpositive to receiving reference standard
(Warnakulasuriya 1990). Two studies were judged to be at unclear
risk of bias (Sweeny 2011; Warnakulasuriya 1991), the remainder
at low risk of bias (Downer 1995; Ikeda 1995; Julien 1995; Julien
1995a; Mathew 1997; Mehta 1986).
Two studies (Chang 2011; Warnakulasuriya 1990) were judged as
being at overall high risk of bias resulting from the flow and timing
domain; three studies were at overall low risk of bias (Downer
1995; Ikeda 1995; Julien 1995a). For the remaining five studies an
unclear risk of bias for at least one of the four domains resulted in
an overall risk of bias judgement of unclear (Julien 1995; Mathew
1997; Mehta 1986; Sweeny 2011; Warnakulasuriya 1991).
Three studies (Chang 2011; Mehta 1986; Sweeny 2011) were
judged as having high overall concerns regarding applicability,
arising from patient selection of high-risk groups. Two studies
(Julien 1995; Julien 1995a) were judged as having low overall
concerns regarding applicability. For the remaining five studies
an unclear concern regarding applicability in the patient selec-
tion domain resulted in an overall applicability judgement of un-
clear (Downer 1995; Ikeda 1995;Mathew 1997;Warnakulasuriya
1990; Warnakulasuriya 1991).
Mouth self examination
Two studies (Elango 2011; Scott 2010) evaluated mouth self ex-
amination as part of an organised screening programme. Risk of
bias for patient selection was judged to be low for both studies.
Concerns regarding applicability for this domain were judged as
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low for one study (Elango 2011) and high for the other (Scott
2010). In this study, the study sample consisted of participants
older than 45 years of age with tobacco habits.
We gave a judgement of unclear risk of bias to both studies for the
index test domain, as it was not reported whether the results of
the index test were interpreted without knowledge of the reference
test. We gave a judgement of low concerns regarding applicability
for this domain.
The risk of bias judgement for the reference standard domain was
low for one study (Scott 2010), being evaluated by a dentist with
training and the reference test being carried out prior to the index
test. We judged the other study (Elango 2011) as unclear risk of
bias as it was unclear whether the conduct of the reference standard
would be likely to correctly classify the condition and also whether
the reference standards were interpreted without knowledge of
the index test. The manuscript states that “the competence of the
healthworkers [reference standard]was confirmedby a trained oral
cancer specialist” but not reported. Consequently the judgements
of concerns regarding applicability for this domain were low (Scott
2010) and unclear (Elango 2011).
Risk of bias was judged to be low for the flow and timing domain
(Scott 2010) and high (Elango 2011) due to a significant number
of withdrawals and exclusions for non-compliance.
The overall risk of bias was judged to be unclear (Scott 2010) and
high (Elango 2011). Concern regarding the overall applicability
of the studies to the review question was high (Scott 2010) due to
patient selection and unclear (Elango 2011) due to the reference
standard being carried out by general health workers specifically
trained for the study rather than a specialist or experienced clini-
cian.
Conventional oral examination compared to
conventional oral examination plus vital rinsing
(Toluidine blue)
We judged this study (Su 2010) which directly compared two in-
dex tests in a randomised controlled trial to be at low risk of bias for
patient selection and index test. Concerns regarding applicability
were judged as high for the patient selection domain as individuals
who “lacked oral habits” such as smoking or betel quid chewing
were eligible for the trial. We judged that there were low concerns
regarding applicability of the index tests. We judged the study to
be at unclear risk of bias whether this was interpreted without
knowledge of the results of the index tests is unclear. There was
low concern regarding applicability of the reference standard. Risk
of bias for the flow and timing domain was judged as low.
Overall risk of bias for this study was judged as unclear, based on
the interpretation of the reference standard. Concern regarding
the overall applicability of the study was high, arising from patient
selection.
Findings
Conventional oral examination
Diagnostic accuracy of COE by a non-specialist compared to a
reference standard was evaluated in 10 studies including 25,568
participants in total, where the target condition was PMD and
cancer of the lip or oral cavity. Pooling of the studies was consid-
ered inappropriate due to the diversity of study and participant
characteristics. The prevalence of PMD or oral cavity cancer in
the diagnostic test accuracy study samples ranged from 1.4% to
50.9%. For the eight studies with prevalence of 10% or lower, the
sensitivity estimates were highly variable, and ranged from 0.50
(95% confidence interval (CI) 0.07 to 0.93) to 0.99 (95%CI 0.97
to 1.00) with uniform specificity estimates around 0.98 (95% CI
0.97 to 1.00). Estimates of sensitivity and specificity were 0.95
(95% CI 0.92 to 0.97) and 0.81 (95% CI 0.79 to 0.83) for one
study with prevalence of 21.6% and 0.97 (95% CI 0.96 to 0.98)
and 0.75 (95% CI 0.73 to 0.77) for one study with prevalence of
51%.
Study prevalence is shown in the coupled forest plot (Figure 2)
along with estimates of sensitivity and specificity and also plotted
in ROC space (Figure 3). All studies for this index test used a
common threshold, the presence of PMDs and oral cancer.
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Figure 3. Summary ROC plot of 1. Conventional oral examination.
A summary is given in the Summary of findings 1.
Mouth self examination
Two studies (Elango 2011; Scott 2010) provided data from34,819
individuals. The prevalence was very different in the two studies:
0.6% and 22.6% respectively. Values of sensitivity were low in
both studies (0.18 (95% CI 0.13 to 0.24) (Elango 2011) and 0.33
(95% CI 0.10 to 0.65) (Scott 2010)) but values of specificity were
higher (1.00 (95%CI 1.00 to 1.00) (Elango 2011) and 0.54 (95%
CI 0.37 to 0.69) (Scott 2010)) (Figure 4; Figure 5).
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Figure 4. Forest plot of 2. Mouth self examination.
Figure 5. Summary ROC plot of 2. Mouth self examination.
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A summary is given in the Summary of findings 2.
Conventional oral examination compared to
conventional oral examination plus vital rinsing
(Toluidine blue)
We included one randomised controlled trial which directly com-
pared the performance of COE alone (3895 individuals) with
COE plus vital staining (4080 individuals) with biopsy and long-
term follow-up through a National Cancer Registry (Su 2010).
This study found a higher detection rate for oral cavity cancer in
the conventional oral examination plus vital rinsing adjunct trial
arm.The detection rate of oral pre-malignant lesions and malig-
nant lesions after referral was 4.6% in the conventional oral ex-
amination plus vital rinsing arm; 4.4% in conventional oral ex-
amination alone. This resulted in a ratio of 1.05 (95% CI 0.74
to 1.41); an incidence rate of oral cancer (x10−5) of 28 compared
to 35.4 and relative incidence rate of 0.79 (95%CI 0.24 to 1.23).
However, the initial screen positive rate was higher in the vital
rinsing arm of the trial (9.5% and 8.3%).
When we consider the trial arms independently, the estimates of
sensitivity and specificity for the target condition of oral cancer in
the trial arm of COE alone were 0.50 (95% CI 0.12 to 0.88) and
0.92 (0.91 to 0.93) with a prevalence of 0.15%; the corresponding
values for the COE with vital rinsing adjunct were 0.40 (95% CI
0.05 to 0.85) and 0.91 (0.90 to 0.91) with a prevalence of 0.13%.
A summary is given in the Summary of findings 3.
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Summary of findings
What is the performance of convent ional oral examinat ion for the detect ion of oral cavity cancer and potent ially malignant
disorders in apparent ly healthy adults?
Population: Oral cavity cancer or potent ially malignant disorder symptom-f ree individuals screened opportunist ically, or
through an organised screening programme
Index test: Convent ional oral examinat ion
Target condition: Oral cavity cancer or potent ially malignant disorder
Reference standard: Examinat ion and clinical evaluat ion by a physician with specialist knowledge or training. Long-term
follow-up was accepted as a suitable reference standard for those part icipants screened negat ive
Studies: Cross-sect ional (consecut ive sample) (9) or validat ion sample in a randomised controlled trial of screening
intervent ion (1)
No. of participants (studies) Effect (95% CI)
Population: Individuals attending for
opportunist ic screening (2), organised
screening programme (4), validat ion as
part of an organised screening pro-
gramme or randomised controlled trial
(3), screening as part of a rout ine surveil-
lance appointment (1)
Index test: Convent ional oral examina-
t ion
Prevalence: Range f rom 1.4% to 50.9%
25,568 (10)
No pooled analysis
Range:
Sensit ivity 0.50 (95% CI 0.07 to 0.93) specif icity 0.
98 (95% CI 0.92 to 1.00)
Sensit ivity 0.99 (95% CI 0.97 to 1.00) specif icity 0.
99 (95% CI 0.99 to 0.99)
CI = conf idence interval
What is the performance of mouth self examinat ion for the detect ion of oral cavity cancer and potent ially malignant disorders
in apparent ly healthy adults?
Population: Oral cavity cancer or potent ially malignant disorder symptom-f ree individuals screened through an organised
screening programme
Index test: Mouth self examinat ion
Target condition: Oral cavity cancer or potent ially malignant disorder
Reference standard: Examinat ion and clinical evaluat ion by a physician with specialist knowledge or training or trained
health worker
Studies: Cross-sect ional studies (or consecut ive series) (2)
No. of participants (studies) Effect (95% CI)
Population: Individuals attending for or-
ganised screening programme (2)
Index test: Mouth self examinat ion
Prevalence: 0.6% and 22.6%
34,819 (2)
No pooled analysis
Sensit ivity 0.18 (95% CI 0.13 to 0.24) specif icity 1.
00 (95% CI 1.00 to 1.00)
Sensit ivity 0.33 (95% CI 0.10 to 0.65) specif icity 0.
54 (95% CI 0.37 to 0.69)
CI = conf idence interval
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What is the performance of vital rinsing (Toluidine blue) as an adjunct to convent ional oral examinat ion compared to
convent ional oral examinat ion alone?
Population: Oral cavity cancer or potent ially malignant disorder symptom-f ree individuals with tobacco habits
Index test: Convent ional oral examinat ion plus vital rinsing (Toluidine blue) compared to convent ional oral examinat ion
alone
Target condition: Oral pre-malignant lesions and malignant lesions
Reference standard: Biopsy. Long-term follow-up through the National Cancer Registry
Studies: RCT (1)
No. of participants (studies) Effect (95% CI)
Population: Individuals attending an or-
ganised screening programme
Study: Direct RCT
Index tests: Convent ional oral examina-
t ion plus vital rinsing (Toluidine blue)
compared with convent ional oral exami-
nat ion alone
Prevalence: 4.6% and 4.4%
7975 (1) Detect ion rate of oral pre-malignant lesions and
malignant lesions af ter referral was 4.6% in con-
vent ional oral examinat ion plus vital rinsing arm;
4.4% in convent ional oral examinat ion alone. Rate
rat io of 1.05 (95% CI 0.74 to 1.41). Incidence rate
of oral cancer (x10−5) of 28 compared to 35.4.
Relat ive incidence rate of 0.79 (95% CI 0.24 to 1.
23)
* Init ial screen posit ive rate higher in the vital
rinsing arm (9.5% and 8.3%)
CI = conf idence interval; RCT = randomised controlled trial
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
16Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D I S C U S S I O N
Summary of main results
Thirteen studies were identified for inclusion evaluating the di-
agnostic accuracy of conventional oral examination (COE), vital
rinsing and mouth self examination. The studies were diverse in
nature with substantial variations in sample prognostic risk factors,
nature of screening test, the experience of personnel conducting
the index test, verification of screen negative and screen positive
individuals, exclusion of individuals from the analysis and large
variation in incidence of disease (including register-based studies)
across included studies. Consequently, the decision was taken that
a meta-analysis of the included studies by index test was inappro-
priate. This is in contrast to some previously published systematic
reviews (e.g. Downer 2004; Moles 2002).
Taken as a body of evidence, the overall quality of the studies was
variable both within and between index tests with only one study
(Julien 1995a) of COE being judged as overall low risk of bias
and overall low concern regarding applicability (Figure 1). Many
of the studies did not fully report on the characteristics and risk
factors of the study sample, particularly important when assessing
the applicability of the results. In five studies the participants could
be considered as ’high risk’ individuals and consequently their
findings are of concern to the applicability of the review question.
Prevalence of potentially malignant disorders (PMD) or malig-
nancy in the diagnostic test accuracy study samples ranged from
1.4% to 50.9% over the different index tests. Estimates should
be interpreted with respect to the diagnostic test accuracy study
prevalence levels. A low prevalence of the target condition effec-
tively results in a lower sample size for diseased participants and
for the calculation of sensitivity. For COE, sensitivity estimates
were highly variable for study level prevalence analogous to those
in the population, and ranged from 0.50 (95% confidence inter-
val (CI) 0.07 to 0.93) to 0.99 (95% CI 0.97 to 1.00). The lower
specificity values observed in the two studies where prevalence was
significantly higher than would normally be observed (20% and
50%) the comparably lower specificity estimates can be explained
at least in part by the higher prevalence. The variation in preva-
lence is reflective of the flow and timing of participants through
the studies, particularly the process of investigation which was
quite different from the flow and timing of the remaining included
studies. All screened positive participants were offered the refer-
ence standard and all participants who attended the referral centre
for subsequent verification received the reference standard. A ran-
dom sample of participants screened negative received differential
verification by the project dentist (diagnostic test accuracy eval-
uation samples of 2193 screen positive and 1350 screen negative
(Warnakulasuriya 1991) and 660 screen positive 1212 and screen
negative (Warnakulasuriya 1990)). For the two studies of mouth
self examination, sensitivity values were 0.18 (95% CI 0.13 to
0.24) and 0.33 (95%CI 0.10 to 0.65) for mouth self examination.
The one study that directly compared COE with COE plus vital
rinsing in a randomised controlled trial found a higher detection
rate for PMD in the trial arm with the vital rinsing adjunct.
Index tests at a prevalence reported in the population (between 1%
and 5%) were better at correctly classifying the absence of PMD
or oral cavity cancer in disease-free individuals than classifying
the presence in diseased individuals. A false negative result from a
screening programme wouldmean that the individuals with PMD
or oral cavity cancer would not be referred for further investiga-
tions; a false positive result would mean a number of individuals
without PMDor oral cavity cancer would receive a positive screen-
ing result, possibly resulting in further excisional investigations
for the patient. Whereas the false positive results could and would
no doubt have financial and other resource implications follow-
ing inappropriate referral, the false negative results indicate that
people with PMD or oral cavity cancer will be missed, possibly to
be diagnosed at a later date when the disease will be more severe.
For mouth self examination, the evidence is equivocal, with poor
values of both sensitivity and specificity in one study. In the other
study, a high value of specificity was accompanied by a very low
sensitivity value. The prevalence of PMD or oral cavity cancer was
high (10.6% and 22.6%) in both studies.
Strengths and weaknesses of the review
The utility of this review is limited in part by the number of in-
cluded studies. A small number of potentially eligible studies were
excluded on the basis that the screened negative individuals did
not receive or report a reference standard. As a result, the num-
ber of false negatives could not be determined. Primary studies
of more recently developed index tests were case-control studies
and consequently ineligible for inclusion through study design.
We took the decision to exclude case-control studies at the proto-
col stage owing to the potential for over estimation of diagnostic
accuracy with this design. However, this has meant that the index
tests evaluated in this review do not include those based on newer
technologies. We would anticipate that those index tests showing
promise at this present time, would be further evaluated with a
more robust study design and therefore be eligible for inclusion in
updates of this review.
Following on from previous systematic reviews in this area (e.g.
Downer 2004), a further five diagnostic accuracy studies have been
identified and were eligible for inclusion in this review. The main
strength of this review is that it evaluated the diagnostic accuracy
of conventional oral examination, vital rinsing and mouth self
examination. All included studieswere assessed formethodological
quality using the QUADAS-2 tool which we specifically adapted
for this review. This enabled the quality of the evidence to be
considered in conjunction with the diagnostic estimates.
Due to the substantial diversity in the nature of the included stud-
ies and the characteristics of the participants it was not appropriate
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to pool the data. Whilst this is not a weakness of the review, the
failure to provide summary estimates of sensitivity and specificity,
in contrast to previous systematic reviews, could be regarded as a
limitation. The range of sensitivity values is likely to have been
influenced by the considerable heterogeneity across the studies. In
future updates should more homogeneous studies be included in
the review, it would be informative to evaluate the influence of
risk factors on estimates of diagnostic accuracy. However, we ac-
knowledge that there was a lack of reported detail in a number of
the included studies regarding the presence or absence of impor-
tant risk factors such as smoking, betel quid chewing and alcohol
consumption.
Participants were recruited into studies that had used a wide range
of criteria from opportunistic screening programmes in company
headquarters to mass screening programmes in South East Asia.
The World Health Organization defines screening as “the appli-
cation of a test or tests to people who are apparently free from the
disease in question in order to distinguish between those that have
the disease from those who probably do not” (Wilson 1968). A
difficulty with a number of the included studies was determining
how representative the screened population were given the settings
for recruitment such as: a company’s headquarters, hospital out-
patient departments and tertiary treatment centres. It could be ar-
gued that the latter sample represents a distinct population with a
much higher risk of developing newdisease due to field change and
one where clinicians are likely to have a higher index of suspicion.
Prevalence of the included studies was in line with what would
be expected; Napier 2008 argues that most authorities agree that
this lies between 1% and 5%. However, the sample prevalence was
particularly high in two studies of COE (Mathew 1997 10.3%,
Ikeda 1995 9.7%) and one study of mouth self examination (Scott
2010 22.6%). In two studies of COE (Warnakulasuriya 1990;
Warnakulasuriya 1991) the sample prevalence calculated from the
two by two table evaluating the diagnostic test accuracy was par-
ticularly high at 21.6% and 50.9%. The screen positive prevalence
for these studies was more in line with population prevalence at
2.25% and 6.23%.
The definitionof a positive lesionwas relatively consistent across all
the studies, although in some studies (e.g. Mehta 1986), a positive
screen could include ’growths suggestive of oral cancer’ or referable
lesions that were neither oral cavity cancer or PMD. Similarly,
the definition of the target condition in the index test differed
from that in the reference standard in some studies. In another
study there was a lack of consistent definition and use of the target
condition for the index and reference tests. As a potential source
of bias, it was not always clear whether the reference standard had
been interpreted with or without knowledge of the index test.
The use of cancer registries or other registries as a reference stan-
dard (e.g. Chang 2011; Su 2010) can be methodologically prob-
lematic, particularly if there is a mismatch in the target condition
being evaluated and the outcome documented in the registry. For
example cancer registries are unlikely to hold data on PMDs that
have not undergone malignant transformation, inducing a mis-
match in the target condition being detected by the index test and
the outcome recorded in the registry. Differential verification bias
can occur if screened positive participants receive biopsy as a refer-
ence standard whilst the screened negative participants are assessed
through a national cancer registry alone. If there is potential for
malignant transformation within the duration of follow-up then
follow-up through registry could be appropriate. Careful thought
should be given to the target condition of the index and reference
standard andwhether this informationwill be adequately recorded
in the registry.
Applicability of findings to the review question
Concerns regarding applicability arose from targeted patient se-
lection of high risk groups for the patient selection domain, where
participants in five of the 13 had either a previous history of head
and neck cancer or were older tobacco smokers. For example, par-
ticipants in one study conducted in a tertiary care clinic (Chang
2011) were all males; and another study recruited former head
and neck cancer patients undergoing routine surveillance visits
(Sweeny 2011). Studies with unclear concerns over in this domain
were those that had omitted important information on patient or
study characteristics which meant that we were unable to deter-
mine whether the participants and settings matched the review
question. There was low concern regarding applicability for the
index test domain for all studies. An unclear judgement for appli-
cability for the reference standard was given to one study where
six people had been identified from the target population to act as
the reference standard (Elango 2011). Although exposed to train-
ing, it is questionable whether trained lay people could act as a
reference standard and there was some concern that the index test
and reference test may have been conducted simultaneously for
those who had not responded initially. A second study (Sweeny
2011) was also judged to be at unclear applicability on this do-
main. There was low concern regarding applicability for the re-
maining 11 studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are known clinical and methodological difficulties associ-
ated with screening for potentially malignant disorders (PMDS)
and cancer of the lip or oral cavity. These include the relatively
low incidence rates, the reluctance of screened positive individ-
uals to attend for follow-up, a lack of linear transition between
pre-malignant and malignant states (Reibel 2003), disagreement
over disease management (Warnakulasuriya 2009) and the relative
cost-effectiveness of mass, selective and opportunistic screening
programmes (Brocklehurst 2011).
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A recent systematic review examined whether screening pro-
grammes for oral cancer could detect the disease and reduce the
associated mortality of the condition (Brocklehurst 2013). One
cluster randomised clinical trial was identified from Kerala in In-
dia. The screening programme comprised of four cycles over a 15-
year period and involved 13 clusters with 191,873 participants.
There was no statistically significant difference in the oral cancer
mortality rates between the screened group (15.4/100,000 person-
years) and the control group (17.1/100,000 person-years). How-
ever, when only high risk individuals were included in the anal-
ysis (users of tobacco or alcohol or both), there was a reported
reduction of 24% in the mortality rate. A statistically significant
reduction was also found in the number of individuals diagnosed
with late stage disease in the screened group (risk ratio 0.81; 95%
confidence interval 0.70 to 0.93). No harms were reported but
the study was assessed to be of high risk of bias. Across the four
cycles (15 years) of the programme, the reported sensitivity of the
visual examination in detecting oral cancer was 67.4% (188/279).
No information on the specificity or the positive predictive value
of the programme was recorded. However, the latter was calcu-
lated based on the published data from the study as the number
of screen-selected oral cancers as a proportion of total screened
positive subjects (confirmed by biopsy), which was 86.5% for oral
cancer.The cost-effectiveness of this study was considered to meet
the standards of the World Health Organization (Subramanian
2009). Selective screening of high risk groups and opportunistic
screening may reduce costs (Speight 2006), but many high risk
patients do not attend general dental practices (Netuveli 2006).
The lack of any formal registration for PMD, in contrast to ma-
lignancy, makes it difficult to estimate possible reductions in mor-
tality due to a screening programme aimed at precursor lesions. In
addition, the efficacy of the early management of PMDs is a con-
troversial area and the evidence base has recently been challenged
(Holmstrup 2007; Holmstrup 2009). Holmstrup has demon-
strated that even if lesions are surgically removed, the risk of ma-
lignant change may remain since the lesion represents only a small
area in a field of damaged mucosa, any part of which may progress
to malignancy.
The results of this review suggest that using the conventional oral
examination (COE) for screening for PMD and oral cancer has
a variable degree of sensitivity (greater than 0.70 in six of the 10
studies) and a consistently high value for specificity (greater than
0.90 in all eight studies). However, there was considerable clini-
cal heterogeneity in the participants forming the study samples,
the application of the index test and reference standard and the
flow and timing of the process. Exploring the primary studies for
sources of heterogeneity has not shown any single factor to con-
sistently influence the accuracy of the screening test. In terms of
test accuracy, there is limited evidence of performance in each of
the different settings, with clinicians or non-clinicians carrying
out the index test etc. which means that the current evidence base
is limited, though COE has been shown to have good estimates
of both sensitivity and specificity in some studies. Further, even
though the evidence of accuracy is not consistently strong, there
is some evidence (Brocklehurst 2013) that implementing COE as
a component of a population screening programme can reduce
mortality and produce stage-shift in a high risk population. Should
such findings be replicated in other studies then it could be argued
that explicit testing of the test accuracy per se of the COE is unnec-
essary, given the positive outcomes on mortality. Emphasis could
be placed on the effectiveness of screening programmes, of which
COE is a component, in reducing morbidity and mortality. This
should be supplemented with information on the consequences
of false negative and false positive screens.
There is insufficient evidence to deviate from the conclusions of
the American Dental Association that oral cancer screening may
detect PMDs and cancer of the lip or oral cavity (Rethman 2010).
General dental practitioners and dental care professionals should
remain vigilant for signs of PMD and oral cancer whilst perform-
ing routine oral examinations in practice.
The sensitivity estimates for mouth self examination were lower
than for COE, though these studies were on different participant
samples and should not be directly compared. There is insufficient
evidence to satisfactorily determine the diagnostic test accuracy
of mouth self examination as part of an organised screening pro-
gramme.
Implications for research
It is clear that there are some methodological shortcomings in the
studies included in this review. TheQUADAS-2 tool has provided
a robust means of assessing the methodological quality of the in-
cluded studies. There is now an opportunity to use this frame-
work, along with the guidance from the Cochrane Diagnostic Test
Accuracy Editorial Group, to ensure that future studies are con-
ducted in a robust manner, with particular attention paid to the
design of the study in the four domains of the QUADAS-2 tool.
It is imperative that studies are reported with sufficient informa-
tion to allow judgement of the merits of the study and its appli-
cability to the review being undertaken. Reporting according to
the STARD checklist should facilitate this process. In particular,
results have been promising in the workplace setting, and for some
opportunistic screening studies.
The population and participant selection should be clearly stated
and carried out to reduce the possibility of sampling bias, prefer-
ably using a consecutive sample. The index test should be un-
dertaken by trained and calibrated screeners, whose threshold for
agreement should be stated a priori. The reference standard should
be both accurate and pragmatic to account for the practical consid-
erations involved in establishing the initial diagnostic test accuracy
component of large population screening programmes. For such
programmes it is not necessary to apply the reference standard to
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the entire programme’s participants, rather an initial evaluation of
test accuracy should be established on a sizeable number of partici-
pants prior to commencement of the screening programme proper.
It is also important to utilize reference standards that capture all
the target conditions under question, not just those that are likely
to be identified through cancer registries. Finally, the flow and
timing of the diagnostic test accuracy study should ensure that the
reference standard is undertaken within a short time frame after
the index test, given the potential for PMD to undergo malignant
transformation and for it to be applied after the index test to avoid
bias being introduced. Where long-term follow-up is used as a ref-
erence standard, measures should be taken to minimise attrition.
Further research on ways to maximise initial participation rates
and also follow-up rates for those screened positive is warranted.
A C K N OW L E D G E M E N T S
Wewould like to thankNHSEducation Scotland and the Scottish
Dental Clinical Effectiveness Programme for their support on this
review; Anne Littlewood (Cochrane Oral Health Group) for her
advice on searching the literature; Derek Richards for his thought-
ful feedback on the protocol; Richard Macey, Kathryn Taylor and
Joanne Leese for help with data extraction and Luisa Fernandez
Mauleffinch and Philip Riley (Cochrane Oral Health Group) for
their assistance in facilitating this review; Jan Clarkson and Helen
Worthington for initiating and facilitating this review.
R E F E R E N C E S
References to studies included in this review
Chang 2011 {published data only}
Chang IH, Jiang RS, Wong YK, Wu SH, Chen FJ, Liu SA.
Visual screening of oral cavity cancer in a male population:
experience from a medical center. Journal of the Chinese
Medical Association 2011;74(12):561–6.
Downer 1995 {published data only}
Downer MC, Evans AW, Hughes Hallett CM, Jullien JA,
Speight PM, Zakrzewska JM. Evaluation of screening for
oral cancer and precancer in a company headquarters.
Community Dentistry and Oral Epidemiology 1995;23(2):
84–8.
Elango 2011 {published data only}
Elango KJ, Anandkrishnan N, Suresh A, Iyer SK, Ramaiyer
SK, Kuriakose MA. Mouth self-examination to improve
oral cancer awareness and early detection in a high-risk
population. Oral Oncology 2011;47(7):620–4.
Ikeda 1995 {published data only}
Ikeda N, Downer MC, Ishii T, Fukano H, Nagao T,
Inoue K. Annual screening for oral cancer and precancer
by invitation to 60-year-old residents of a city in Japan.
Community Dental Health 1995;12(3):133–7.
Julien 1995 {published data only}
Jullien JA, Downer MC, Zakrzewska JM, Speight PM.
Evaluation of a screening test for the early detection of oral
cancer and precancer. Community Dental Health 1995;12:
3–7.
Julien 1995a {published data only}
Jullien JA, Downer MC, Zakrzewska JM, Speight PM.
Evaluation of a screening test for the early detection of oral
cancer and precancer. Community Dental Health 1995;12:
3–7.
Mathew 1997 {published data only}
∗ Mathew B, Sankaranarayanan R, Sunilkumar KB,
Kuruvila B, Pisani P, Nair MK. Reproducibility and validity
of oral visual inspection by trained health workers in the
detection of oral precancer and cancer. British Journal of
Cancer 1997;76(3):390–4.
Ramadas K, Sankaranarayanan R, Jacob BJ, Thomas G,
Somanathan T, Mahé C, et al. Interim results from a cluster
randomized controlled oral cancer screening trial in Kerala,
India. Oral Oncology 2003;39(6):580–8.
Sankaranarayanan R, Mathew B, Jacob BJ, Thomas G,
Somanathan T, Pisani P, et al. Early findings from a
community-based, cluster-randomized, controlled oral
cancer screening trial in Kerala, India. The Trivandrum
Oral Cancer Screening Study Group. Cancer 2000;88(3):
664–73.
Sankaranarayanan R, Ramadas K, Thara S, Muwonge
R, Thomas G, Anju G, et al. Long term effect of visual
screening on oral cancer incidence and mortality in a
randomized trial in Kerala, India. Oral Oncology 2013;49
(4):314–21.
Mehta 1986 {published data only}
Mehta FS, Gupta PC, Bhonsle RB, Murti PR, Daftary DK,
Pindborg JJ. Detection of oral cancer using basic health
workers in an area of high oral cancer incidence in India.
Cancer Detection and Prevention 1986;9(3-4):219–25.
Scott 2010 {published data only}
Scott SE, Rizvi K, Grunfeld EA, McGurk M. Pilot study to
estimate the accuracy of mouth self-examination in an at-
risk group. Head and Neck 2010;32(10):1393–401.
Su 2010 {published data only}
Su WW, Yen AM, Chiu SY, Chen TH. A community-based
RCT for oral cancer screening with toluidine blue. Journal
of Dental Research 2010;89(9):933–7.
Sweeny 2011 {published data only}
Sweeny L, Dean NR, Magnuson JS, Carroll WR, Clemons
L, Rosenthal EL. Assessment of tissue autofluorescence
and reflectance for oral cavity cancer screening. Journal
of Otolaryntology - Head and Neck Surgery 2011;145(6):
956–60.
20Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Warnakulasuriya 1990 {published data only}
Warnakulasuriya KA, Ekanayake AN, Sivayoham S,
Stjernswärd J, Pindborg JJ, Sobin IH, et al. Utilization
of primary health care workers for early detection of oral
cancer and precancer cases in Sri Lanka. Bulletin of the
World Health Organization 1984;62(2):243–50.
∗ Warnakulasuriya S, Pindborg JJ. Reliability of oral
precancer screening by primary health care workers in Sri
Lanka. Community Dental Health 1990;7(1):73–9.
Warnakulasuriya 1991 {published data only}
Warnakulasuriya KA, Nanayakkara BG. Reproducibility of
an oral cancer and precancer detection program using a
primary health care model in Sri Lanka. Cancer Detection
and Prevention 1991;15(5):331–4.
References to studies excluded from this review
Bhalang 2008 {published data only}
Bhalang KA, Suesuwan A, Dhanuthai K, Sannikorn P,
Luangjarmekorn L, Swasdison S. The application of acetic
acid in the detection of oral squamous cell carcinoma. Oral
Surgery, Oral Medicine, Oral Pathology, Oral Radiology and
Endodontics 2008;106(3):371–6.
Bowles 1973 {published data only}
Bowles DA Jr, Levin ES, Hasler JF. A comparison of two
cytologic methods for mass screening against oral cancer.
Journal of Oral Surgery 1973;31(11):830–6.
Chen 2007 {published data only}
Chen YW, Lin JS, Fong JH, Wang IK, Chou SJ, Wu CH,
et al. Use of methylene blue as a diagnostic aid in early
detection of oral cancer and precancerous lesions. British
Journal of Oral and Maxillofacial Surgery 2007;45(7):590–1.
Csépe 2007 {published data only}
Csépe P, Bánóczy J, Dombi C, Forrai J, Gyenes M, Döbrossy
L. Model program for screening oral cancers in the Roma
population. Magyar Onkologia 2007;51(2):95–101.
Fernández Garrote 1995 {published data only}
Fernández Garrote L, Sankaranarayanan R, Lence Anta JJ,
Rodriguez Salvá A, Maxwell Parkin D. An evaluation of the
oral cancer control program in Cuba. Epidemiology 1995;6
(4):428–31.
Hapner 2011 {published data only}
Hapner ER, Wise JC. Results of a large-scale head and neck
cancer screening of an at-risk population. Journal of Voice
2011;25(4):480–3.
Huber 2004 {published data only}
Huber MA, Bsoul SA, Terzhalmy GT. Acetic acid wash
and chemiluminescent illumination as an adjunct to
conventional oral soft tissue examination for the detection
of dysplasia: a pilot study. Quintessence International 2004;
35(5):378–84.
Huff 2009 {published data only}
Huff K, Stark PC, Solomon LW. Sensitivity of direct tissue
fluorescence visualization in screening for oral premalignant
lesions in general practice. General Dentistry 2009;57(1):
34–8.
Leocata 2007 {published data only}
Leocata P, D’Alessandro A, D’Amario M, Barone A,
Giannoni M. A screening program for the early detection
and prevention of oral cancer. Journal of Plastic Dermatology
2007;3(1):71–5.
Lim 2003 {published data only}
LimK,Moles DR, DownerMC, Speight PM.Opportunistic
screening for oral cancer and precancer in general dental
practice: results of a demonstration study. British Dental
Journal 2003;194(9):497–502.
Nagao 2000 {published data only}
∗ Nagao T, Ikeda N, Fukano H, Miyazeki H, Yano M,
Warnakulasuriya S. Outcome following a population
screening programme for oral cancer and precancer in
Japan. Oral Oncology 2000;36:340–6.
Nagao T, Warnakulasuriya S. Annual screening for oral
cancer detection. Cancer Detection and Prevention 2003;27:
333–7.
Nagao T, Warnakulasuriya S, Ikeda N, Fukano H, Fujiwara
K, Miyazaki H. Oral cancer screening as an integral part of
general health screening in Tokoname City, Japan. Journal
of Medical Screening 2000;7(4):203–8.
Oh 2007 {published data only}
Oh ES, Laskin DM. Efficacy of the ViziLite system in
the identification of oral lesions. Journal of Oral and
Maxillofacial Surgery 2007;65(3):424–6.
Poh 2007 {published data only}
Poh CF, Hislop G, Currie B, Lee R, Sikorski S, Zed C,
et al. Oral cancer screening in a high-risk underserved
community--Vancouver Downtown Eastside. Journal of
Health Care for the Poor and Underserved 2007;18(4):
767–78.
Srivasta 1971 {published data only}
Srivastava YC, Mathur MN. Toluidine blue staining test for
early detection of oral cancer: an adjunct to biopsy. Dental
Digest 1971;77(7):400–3.
Vahidy 1972 {published data only}
Vahidy NA, Zaidi SH, Jafarey NA. Toludine blue test for
detection of carcinoma of the oral cavity: an evaluation.
Journal of Surgical Oncology 1972;4(5):434–8.
Warnakulasuriya 2010 {published data only}
Warnakulasuriya S, Kashyap R, Dasanayake AP. Is workplace
screening for potentially malignant oral disorders feasible in
India?. Journal of Oral Pathology and Medicine 2010;39(9):
672–6.
References to studies awaiting assessment
Barrellier 1980 {published data only}
Barrellier P, Rame JP, Chasle J, Souquières Y. Detection of
buccal cavity cancers with toluidine blue (author’s transl).
Revue de Stomatologie et de Chirurgie Maxillo-Faciale 1980;
81(6):364–7.
Barrellier 1982 {published data only}
Barrellier P, Rame JP, Chasle J, Souquières Y, Lecacheux B.
Detection of cancer of the oral cavity using toluidine blue.
Actualités Odonto-Stomatologiques 1982;36(137):87–92.
21Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Marzouki 2012 {published data only}
Marzouki HZ, Tuong Vi Vu T, Ywakim R, Chauvin P,
Hanley J, Kost KM. Use of fluorescent light in detecting
malignant and premalignant lesions in the oral cavity: a
prospective, single-blind study. Journal of Otolaryngology -
Head and Neck Surgery 2012;41(3):164–8.
Vacher 1999 {published data only}
Vacher C, Legens M, Rueff B, Lezy JP. Screening of
cancerous and precancerous lesions of the oral mucosa in
an at-risk population. Revue de Stomatologie et de Chirurgie
Maxillo-Faciale 1999;100:180–3.
References to ongoing studies
Kulak 2010 {published data only}
Kulak J, Franzmann E. The use of autofluorescence in
detection of oral lesions. The Laryngoscope 2010;120(S3):
S40.
Additional references
American Cancer Society 1992
American Cancer Society. Update January 1992: the
American Cancer Society guidelines for the cancer-related
checkup. CA: a Cancer Journal for Clinicians 1992;42(1):
44–5.
Bessell 2011
Bessell A, Glenny A-M, Furness S, Clarkson JE, Oliver R,
Conway DI, et al. Interventions for the treatment of oral
and oropharyngeal cancers: surgical treatment. Cochrane
Database of Systematic Reviews 2011, Issue 9. [DOI:
10.1002/14651858.CD006205.pub3]
Brinkmann 2011
Brinkmann O, Kastratovic DA, Dimitrijevic MV,
Konstantinovic VS, Jelovac DB, Antic J, et al. Oral
squamous cell carcinoma detection by salivary biomarkers
in a Serbian population. Oral Oncology 2011;47(1):51–5.
Brocklehurst 2010
Brocklehurst PR, Baker SR, Speight PM. Oral cancer
screening: what have we learnt and what is there still to
achieve?. Future Oncology 2010;6(2):299–304.
Brocklehurst 2011
Brocklehurst PR, Ashley JR, Tickle M. Patient assessment
in general dental practice - risk assessment or clinical
monitoring?. British Dental Journal 2011;210(8):351–4.
Brocklehurst 2013
Brocklehurst P, Kujan O, O’Malley LA, Ogden G, Shepherd
S, Glenny AM. Screening programmes for the early
detection and prevention of oral cancer. Cochrane Database
of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/
14651858.CD004150.pub4]
Buchen 2011
Buchen L. Cancer: Missing the mark. Why is it so hard
to find a test to predict cancer?. Nature 2011;471(7339):
428–32.
Cancer Research UK
Cancer Research UK. http://www.cancerresearchuk.org/
cancer-info/cancerstats/types/oral/uk-oral-cancer-statistics.
Conway 2008
Conway DI, Petticrew M, Marlborough H, Berthiller J,
Hashibe M, Macpherson LM. Socioeconomic inequalities
and oral cancer risk: a systematic review and meta-analysis
of case-control studies. International Journal of Cancer
2008;122(12):2811–9.
Downer 2004
Downer MC, Moles DR, Palmer S, Speight PM. A
systematic review of test performance in screening for oral
cancer and precancer. Oral Oncology 2004;40(3):264–73.
Faggiano 1997
Faggiano F, Partanen T, Kogevinas M, Boffetta P.
Socioeconomic differences in cancer incidence and
mortality. In: Kogevinas M, Pearce N, Susser M, Boffetta
P editor(s). Social Inequalities and Cancer. Lyon: IARC
Scientific Publications No 138. International Agency for
Research in Cancer, 1997.
Fedele 2009
Fedele S. Diagnostic aids in the screening of oral cancer.
Head & Neck Oncology 2009;1:5.
Ferlay 2010
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin
DM. Estimates of worldwide burden of cancer in 2008:
GLOBOCAN 2008. International Journal of Cancer 2010;
127(12):2893–917.
Freedman 2007
Freedman ND, Abnet CC, Leitzmann MF, Hollenbeck
AR, Schatzkin A. Prospective investigation of the cigarette
smoking-head and neck association by sex. Cancer 2007;
110(7):1593–601.
Furness 2011
Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver
R, Clarkson JE, et al. Interventions for the treatment
of oral cavity and oropharyngeal cancer: chemotherapy.
Cochrane Database of Systematic Reviews 2011, Issue 4.
[DOI: 10.1002/14651858.CD006386.pub3]
Garg 2005
Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP,
Devereaux PJ, Beyene J, et al. Effects of computerized
clinical decision support systems on practitioner
performance and patient outcomes: a systematic review.
JAMA 2005;293(10):1223–38.
Glenny 2010
Glenny AM, Furness S, Worthington HV, Conway DI,
Oliver R, Clarkson JE, et al. Interventions for the treatment
of oral cavity and oropharyngeal cancer: radiotherapy.
Cochrane Database of Systematic Reviews 2010, Issue 12.
[DOI: 10.1002/14651858.CD006387.pub2]
Holmstrup 2006
Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term
treatment outcome of oral premalignant lesions. Oral
Oncology 2006;42(5):461–74.
Holmstrup 2007
Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral
premalignant lesions: is a biopsy reliable?. Journal of Oral
Pathology and Medicine 2007;36(5):262-6.
22Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Holmstrup 2009
Holmstrup P. Can we prevent malignancy by treating
premalignant lesions?. Oral Oncology 2009;45:549–50.
Jaber 2003
Jaber MA, Porter SR, Speight P, Eveson JW, Scully C.
Oral epithelial dysplasia: clinical characteristics of western
European residents. Oral Oncology 2003;39(6):589–96.
Jemal 2008
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al.
Cancer statistics, 2008. CA: A Cancer Journal for Clinicians
2008;58(2):71–96.
La Vecchia 1997
La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G,
Negri E. Epidemiology and prevention of oral cancer. Oral
Oncology 1997;33(5):302–12.
Landis 1977
Landis JR, Koch GG. The measurement of observer
agreement for categorical data. Biometrics 1977;33(1):
159–74.
Lee 2009
Lee JM, Garon E, Wong DT. Salivary diagnostics.
Orthodontics and Craniofacial Research 2009;12(3):206–11.
Leeflang 2008
Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane
Diagnostic Test Accuracy Working Group. Systematic
reviews of diagnostic test accuracy. Annals of Internal
Medicine 2008;149(12):889–97.
Leston 2010
Seoane Leston J, Diz Dios P. Diagnostic clinical aids in oral
cancer. Oral Oncology 2010;46(6):418–22.
Li 2006
Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, et
al. Serum circulating human mRNA profiling and its utility
for oral cancer detection. Journal of Clinical Oncology 2006;
24(11):1754–60.
Lingen 2008
Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical
evaluation of diagnostic aids for the detection of oral cancer.
Oral Oncology 2008;44(1):10–22.
Liu 2006
Liu JL, Wyatt JC, Deeks JJ, Clamp S, Keen J, Verde P, et
al. Systematic reviews of clinical decision tools for acute
abdominal pain. Health Technology Assessment 2006;10(47):
1–167.
Liu 2012
Liu JLY, Walsh T, Kerr AR, Lingen M, Brocklehurst P,
Ogden G, et al. Diagnostic tests for oral cancer and
potentially malignant disorders in patients presenting
with clinically evident lesions. Cochrane Database of
Systematic Reviews 2012, Issue 12. [DOI: 10.1002/
14651858.CD010276]
Lodi 2006
Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A.
Interventions for treating oral leukoplakia. Cochrane
Database of Systematic Reviews 2006, Issue 4. [DOI:
10.1002/14651858.CD001829.pub3]
Macfarlane 1995
Macfarlane GJ, Zheng T, Marshall JR, Boffetta P, Niu S,
Brasure J, et al. Alcohol, tobacco, diet and the risk of oral
cancer: a pooled analysis of three case-control studies.
European Journal of Cancer. Part B, Oral Oncology 1995;
31B(3):181–7.
Mashberg 1988
Mashberg A, Feldman LJ. Clinical criteria for identifying
early oral and oropharyngeal carcinoma: erythroplasia
revisited. American Journal of Surgery 1988;156(4):273–5.
Mashberg 1995
Mashberg A, Samit A. Early diagnosis of asymptomatic oral
and oropharyngeal squamous cancers. CA: A Cancer Journal
for Clinicians 1995;45(6):328–51.
McGurk 2010
McGurk M, Scott SE. The reality of identifying early oral
cancer in the general dental practice. British Dental Journal
2010;208(8):347–51.
Moles 2002
Moles DR, Downer MC, Speight PM. Meta-analysis of
measures of performance reported in oral cancer and
precancer screening studies. British Dental Journal 2002;
192(6):340–4.
Napier 2008
Napier SS, Speight PM. Natural history of potentially
malignant oral lesions and conditions: an overview of the
literature. Journal of Oral Pathology and Medicine 2008;37
(1):1–10.
Netuveli 2006
Netuveli G, Sheiham A, Watt RG. Does the ’inverse
screening law’ apply to oral cancer screening and regular
dental check-ups?. Journal of Medical Screening 2006;13(1):
47–50.
Ogden 2005
Ogden GR. Alcohol and oral cancer. Alcohol 2005;35(3):
169–73.
Parkin 2001
Parkin DM. Global cancer statistics in the year 2000. Lancet
Oncology 2001;2(9):533–43.
Patton 2008
Patton LL, Epstein JB, Kerr AR. Adjunctive techniques for
oral cancer examination and lesion diagnosis: a systematic
review of the literature. Journal of American Dental
Association 2008;139(7):896–905.
Petti 2003
Petti S. Pooled estimate of world leukoplakia prevalence: a
systematic review. Oral Oncology 2003;39(8):770–80.
Reibel 2003
Reibel J. Prognosis of oral pre-malignant lesions:
significance of clinical, histopathological, and molecular
biological characteristics. Critical Reviews in Oral Biology
and Medicine 2003;14(1):47–62.
23Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rethman 2010
Rethman MP, Carpenter W, Cohen EE, Epstein J,
Evans CA, Flaitz CM, et al. Evidence-based clinical
recommendations regarding screening for oral squamous
cell carcinomas. Journal of the American Dental Association
2010;141(5):509–20.
RevMan 2012 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012.
Rogers 2009
Rogers SN, Brown JS, Woolgara JA, Lowe D, Magennis P,
Shaw RJ, et al. Survival following primary surgery for oral
cancer. Oral Oncology 2009;45(3):201–11.
Rosin 2006
National Institute of Dental and Craniofacial Research.
Bringing the promise of molecular medicine to oral
cancer screening. http://www.nidcr.nih.gov/Research/
ResearchResults/InterviewsOHR/TIS032006.htm (accessed
18th April 2011).
Rusthoven 2010
Rusthoven KE, Raben D, Song JI, Kane M, Altoos TA,
Chen C. Survival and patterns of relapse in patients with
oral tongue cancer. Journal of Oral and Maxillofacial Surgery
2010;68(3):584–9.
Sankaranarayanan 1997
Sankaranarayanan R. Health care auxiliaries in the detection
and prevention of oral cancer. Oral Oncology 1997;33(3):
149–54.
Scully 2000b
Scully C, Shotts R. ABC of oral health. Mouth ulcers and
other causes of orofacial soreness and pain. BMJ 2000;321
(7254):162–5.
Scully 2009
Scully C, Bagan J. Oral squamous cell carcinoma overview.
Oral Oncology 2009;45(4-5):301–8.
Silverman 1984
Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia
and malignant transformation. A follow-up study of 257
patients. Cancer 1984;53(3):563–8.
Speight 2006
Speight PM, Palmer S, Moles DR, Downer MC, Smith DH,
Henriksson M, et al. The cost-effectiveness of screening for
oral cancer in primary care. Health Technology Assessment
2006;10(14):1–144.
Subramanian 2009
Subramanian S, Sankaranarayanan R, Bapat B, Somanathan
T, Thomas G, Matthew B, et al. Cost-effectiveness of
oral cancer screening: results from a cluster randomized
controlled trial in India. Bulletin of the World Health
Organization 2009;87(3):200-6.
US Preventive Services Task Force
US Preventive Services Task Force. http://
www.uspreventiveservicestaskforce.org/ (accessed 8th April
2011).
van der Waal 2009
van der Waal I. Potentially malignant disorders of the oral
and oropharyngeal mucosa: terminology, classification and
present concepts of management. Oral Oncology 2009;45
(4-5):317–23.
Warnakulasuriya 2007
Warnakulasuriya S, Johnson NW, van der Waal I.
Nomenclature and classification of potentially malignant
disorders of the oral mucosa. Journal of Oral Pathology and
Medicine 2007;36(10):575–80.
Warnakulasuriya 2009
Warnakulasuriya S. Global epidemiology of oral and
oropharyngeal cancer. Oral Oncology 2009;45(4-5):309–16.
Whiting 2004
Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM,
Kleijnen J. Sources of variation and bias in studies of
diagnostic accuracy: a systematic review. Annals of Internal
Medicine 2004;140(3):189–202.
Whiting 2011
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks
JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the
quality assessment of diagnostic accuracy studies. Annals of
Internal Medicine 2011;155(8):529–36.
Wilson 1968
Wilson JM, Jungner YG. Principles and practice of mass
screening for disease. Boletín de la Oficina Sanitaria
Panamericana 1968;65(4):281–393.
Wyatt 1995
Wyatt JC, Altman DG. Commentary: Prognostic models:
clinically useful or quickly forgotten?. BMJ 1995;311:1539.
Yusof 2006
Yusof ZY, Netuveli G, Ramli AS, Sheiham A. Is
opportunistic oral cancer screening by dentists feasible? An
analysis of the patterns of dental attendance of a nationally
representative sample over 10 years. Oral Health and
Preventive Dentistry 2006;4(3):165–71.
∗ Indicates the major publication for the study
24Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chang 2011
Study characteristics
Patient sampling Method of patient selection: Optional screening programme at a tertiary referral centre in central
Taiwan. “All male patients who visited our clinic (Otolaryngology or Dental Department) aged
18 or older were eligible for enrolment in this study.” “Those who were reluctant to undergo oral
screening were excluded”
Patient characteristics and set-
ting
13,878 patients enrolled from March 2005 to January 2010
Age: Mean age 54.6 years (sd 18.4 range 18 to 97 years)
Sex: Male population, reasons for single sex sample not stated
SES: Not stated
Ethnicity: Not stated
Stated risk factors: 2844 habitual smokers; 943 habitual betel quid chewers; 1955 habitual drinkers
Previous history: Not stated
Location: Taiwan
Clinical setting: Tertiary academic medical centre. Veterans General Hospital
Index tests Index test: “..visual screening of the oral cavity was performed by experienced otolaryngologists or
dentists under adequate lighting and with proper instruments”
Description of positive case definition by index test as reported: “A non-healing ulcer for more than
2 weeks, a persistent white or red lesion, a lesion that bled easily, or an irregular surface lesion inside
the oral cavity were regarded as positive findings.” Positive lesions indicative of oral cavity cancer
Sequence of tests: Index followed by reference
Training or calibration: Not stated
Blinding of examiners: Not stated
Conflict of interests: Authors declare no conflict of interest
Target condition and reference
standard(s)
Target condition: Oral cavity cancer
Reference standard: Punch biopsy with histopathology of abnormal lesions. “If the patient did not
agree to further biopsy, follow-up was strongly recommended.” Follow-up of entire cohort. “We
further crosslinked the entire screened cohort with the Taiwan Cancer Registry database”
Description of positive case definition by reference test as reported: Oral cavity cancer
Training or calibration: Not stated
Blinding of examiners: Not stated
Prevalence of the target condition on the sample: 285/13,606 2.1%
Flow and timing Time interval and any interventions between index test(s) and reference standard: Not reported
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: “A total of 272 participants (37.5%) with abnormal oral cavity
lesions were lost to follow-up and no further pathological report could be obtained.” “In order not
to confound further analyses, we excluded those with positive lesions/yet no further biopsy during
the follow-up period. Although 272 participants were excluded from the final analysis, there was
little impact on the power of the statistic analysis due to the large population size”
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: “We further cross linked the entire screened
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cohort with the Taiwan Cancer Registry database.” Not reported when this was done (follow-up
time) for entire cohort
Comparative
Notes Sensitivity and specificity data reported for oral cavity cancer. Index test target condition clinically
suspicious oral lesions; reference standard target condition oral cancer
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
Downer 1995
Study characteristics
Patient sampling Method of patient selection: Employees (40 years or over) in a workplace setting responding to
a screening invitation. Screening programme was widely publicised through in-house magazine,
information leaflets, video in hallway. Participation rate 53%
Patient characteristics and set-
ting
292/553 (53%) of workers responded to the screening invitation. Additional 17 screened from a
separate site
Age: ≥40 years
Sex: Not stated
SES: 31.8% lower occupational level, 68.2% management grade or above
Ethnicity: Not stated
Stated risk factors: HPV - not stated; smoking - smokers included in sample but proportions not
specified; alcohol - drinkers included in sample but proportions not specified
Previous history: Not stated
Location: Commercial company. London, UK
Clinical setting: Onsite company dental practice
Index tests Index test: Systematic visual examination by 2 general dental practitioners
Description of positive case definition by index test as reported: “...if a white patch, red patch or
ulcer of greater than two weeks duration was detected.” Further qualified into lesions that should
be regarded as malignant or pre-malignant (positive) and those to be regarded as negative
Sequence of tests: Index test followed by reference standard
Training or calibration: “...who had not received any specific training except for instruction in
the screening procedure and the criteria for a positive or negative test.” No specific training and
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standardisation of screeners nor calibration
Blinding of examiners: Index test completed before reference standard
Conflict of interests: Not stated
Target condition and reference
standard(s)
Target condition: As for the index test: Carcinoma, leukoplakia, erythroplakia, lichen planus, lupus
erythematosus, submucous fibrosis, actinic keratosis
Reference standard: Visual examination by an oral medicine specialist with “...access to any relevant
diagnostic aids, including biopsy if considered necessary”
Description of positive case definition by reference test as reported: “...if a white patch, red patch or
ulcer of greater than two weeks duration was detected.” Further qualified into lesions that should
be regarded as malignant or pre-malignant (positive) and those to be regarded as negative
Training or calibration: Not stated
Blinding of examiners: Index test completed before reference standard. “...who was unaware of the
findings of the screener”
Prevalence of the target condition on the sample: 17/309 5.5%
Flow and timing Time interval and any interventions between index test(s) and reference standard: Immediately
following attendance at screening session: “After screening...”
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: “A number of staff who were screened will not have been
included in the evaluation since they were unable to attend at one of the dedicated sessions and
were therefore not examined by the specialist diagnostician.” Separate values for those attending the
screening and reference standard examination not reported
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
Comparative
Notes 68.2% proportion of participants at management grade or above. 53% participation rate
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Low
Elango 2011
Study characteristics
Patient sampling Method of patient selection: “The study population was distributed in two Panchayats (local ad-
ministrative unit in villages) with 33 subunits. Brochures were sequentially distributed to all the
houses in the subunits.” After a lapse of 4 weeks “Health workers attempted to locate individuals
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up to a maximum of three times, incase they were unavailable during the first visit”
Patient characteristics and set-
ting
Results available for 34,766/48,080 eligible participants. “48,080 (83.3%) subjects, above the age
of 10 years, were eligible for the study”
Age: Median age band 30-39 years
Sex: 17,158 male 17,608 female
SES: Not stated
Ethnicity: Not stated
Stated risk factors: Tobacco smoking / chewing pan 10,644; alcohol consumption 3844
Previous history: Not stated
Location: Kerala, India. “It was carried out in a high-risk population of 57,704, in the coastal villages
of Kerala, India, where there is a high incidence of oral cancer and prevalence of risk factors”
Clinical setting: Participants’ own homes
Index tests Index test: Mouth self examination in accordance with brochures specifically designed for this
population. “A brochure was developed, which contained information on oral cancer, its risk factors
and the methods to perform MSE. It also had instructions to report to the oral cancer-screening
clinic, in case of identification of any suspicious lesions”
Description of positive case definition by index test as reported:White patch, red patch, non-healing
ulcers, difficulty in opening mouth, other oral symptoms (burning sensation)
Sequence of tests: Index test followed by reference standard
Training or calibration: Dedicated brochure instructed on mouth self examination technique
Blinding of examiners: No description of timing or recording of mouth self examination in relation
to visit by health worker 4 weeks after screening exam (mouth self examination could have been
carried out concurrently)
Conflict of interests: None. “The project was supported by Government of India, Department of
Science and Technology, research grant (SSD/SCP/060/2005)”
Target condition and reference
standard(s)
Target condition: Oral cancer and potentially malignant lesions
Reference standard: “Six health workers recruited from the population wherein the study was con-
ducted...”
Description of positive case definition by reference test as reported: “The presence (including site
and provisional diagnosis) and absence of potentially malignant oral lesions (ulcers, white or red
patches, or lumps/swellings) were noted on a proforma”
Training or calibration: “Six health workers underwent one month training on oral cancer in a
comprehensive cancer center, which coordinated the study. The training consisted of a didactic
course on oral cancer, its risk factors, clinical findings of potentially malignant and malignant
oral lesions, and methods to perform oral visual examination. WHO Guide to epidemiology and
diagnosis of oral mucosal diseases and conditions was used as the referencemanual. The competence
of the health workers was confirmed by a trained oral cancer specialist.” Calibration not stated
Blinding of examiners: Not stated
Prevalence of the target condition on the sample: 219/34,766 0.63%
Flow and timing Time interval and any interventions between index test(s) and reference standard: “After a lapse of
4 weeks, the trained health workers performed oral visual examination on all the members of the
households above the age of 10 years”
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: From 48,080 participants initially eligible, 5761 unavailable
for examination by reference standard, and a further 7553 “who did not comply with the study
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procedure were excluded from the study population.” Results available for 34,766 participants (38%
attrition)
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: Reference standard carried out by a trained
health worker
Comparative
Notes Possible bias introduced through exclusion of participants that did not comply with the procedure.
Participants located in area of high prevalence of oral cancer and potentially malignant lesions
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
31Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Elango 2011 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Ikeda 1995
Study characteristics
Patient sampling Method of patient selection: Postal invitation to 60-year old residents to participate in an annual
mass screening programme
Patient characteristics and set-
ting
154 from last screening exercise (5187 eligible during reported 7 years of the programme from 1986
to 1993)
Age: 60 years of age
Sex: Not stated
SES: Not stated
Ethnicity: Not stated
Stated risk factors: Not stated
Previous history: Not stated
Location: Japan
Clinical setting: City health centre
Index tests Index test: Standard visual examination carried out by 4 general dental practitioners. “Lesions were
recorded on a standard WHO form modified for local conditions”
Description of positive case definition by index test as reported: “The screen was recorded as positive
for oral cancer or precancer if the examiner considered a carcinoma, erythroplakia, lichen planus
or chronic candidosis was present.” Types of lesion categorised as malignancy, malignant potential,
benign characterisation or absence
Sequence of tests: Index followed by reference. “Following screening individual consultation was
provided on site for all those examined...”
Training or calibration: Trained according to WHO guidelines. Calibration for the 4 dentists was
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reported. Kappa scores were slight to moderate (0.08 to 0.44) for classification of lesions and
moderate to substantial (0.39 to 0.78) for identifying the presence/absence of lesions
Blinding of examiners: Index test completed prior to reference
Conflict of interests: Not stated
Target condition and reference
standard(s)
Target condition: As for index test.
Reference standard: “..assessed by an oral medicine specialist”
Description of positive case definition by reference test as reported: Presence or absence of malignant
or pre-malignant oral lesions and classification of lesions
Training or calibration: Previously calibrated, details not reported
Blinding of examiners: Not explicitly stated but “...independent clinical diagnoses of the instructor
carried out concurrently”
Prevalence of the target condition in the sample: 15/154 9.7%
Flow and timing Time interval and any interventions between index test(s) and reference standard: “Following screen-
ing...” consultation undertaken on same day
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: All received index and reference (data fully reported for results
of most recent screening exercise only)
Characteristics and proportion of individuals who received a reference standard other than exam-
ination and clinical evaluation by a specialist physician: Screened positive did receive biopsy but
data taken from table of clinical diagnosis of specialist (Table 1)
Comparative
Notes Definition of positive threshold could underestimate accuracy
802/5187 eligible residents presented for screening during reported 7 years of the programme from
1986 to 1993
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Julien 1995
Study characteristics
Patient sampling Method of patient selection: Participants recruited “...by the screener or the specialist from the
various outpatient departments of the hospital.” Method of selection of participants at the dental
hospital is unclear
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Patient characteristics and set-
ting
1042 participants (total population not reported)
Participant characteristics are reported across both studies
Age: 40 years or over; mean 56 years
Sex: 892 male 1135 female
SES: Not stated
Ethnicity: Not stated
Stated risk factors: 162 heavy smoker 608 moderate smoker 1257 non-smoker; 61 heavy drinker
527 moderate drinker 1439 light drinker
Previous history: Not stated
Location: UK
Clinical setting: Out-patient departments of a dental hospital
Index tests Index test: Thorough visual examination of the surface of the oral mucosa according to the British
Postraduate Medical Federation, 1991, by either a general dental practitioner, a community dental
officer or a junior hospital dentist (24 screeners)
Description of positive case definition by index test as reported: “A lesion was defined as positive
when a white patch, red patch, or an ulcer of longer than two weeks duration was detected.” “The
screeners were also instructed to include lesions of lupus erythematosus, submucous fibrosis or
actinic keratosis as positive.” All types of lichen planus were also regarded as positive
Sequence of tests: Index followed by reference
Training or calibration: “..screeners advised of diagnostic criteria which should result in a positive
or negative screen .....no formal training or standardisation was undertaken”
Blinding of examiners: Index test completed before reference
Conflict of interests: Supported by grant from the Department of Health, UK
Target condition and reference
standard(s)
Target condition: Oral cancer and pre-cancer
Reference standard: Visual examination by second dental specialist who was able to refer subjects
for further tests or review as appropriate (single specialist)
Description of positive case definition by reference test as reported: As for index test. “A lesion was
defined as positive when a white patch, red patch, or an ulcer of longer than two weeks duration was
detected.” “The screeners were also instructed to include lesions of lupus erythematosus, submucous
fibrosis or actinic keratosis as positive.” All types of lichen planus were also regarded as positive
Training or calibration: Not stated but quoted as “a specialist.” Single examiner so no calibration
Blinding of examiners: Index test completed before reference. “The results were also recorded on
a standard form which was collated with the screeners’ form only after completion.” “All subjects
were examined by a specialist who provided an independent definitive diagnosis”
Prevalence of the target condition on the sample: 32/1042 3.1%
Flow and timing Time interval and any interventions between index test(s) and reference standard: Not explicit,
however, reasonable to assume both conducted on same visit
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: None
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
Comparative
Notes
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Julien 1995a
Study characteristics
Patient sampling Methodof patient selection: List of registeredmedical practice patients obtained andpostal invitation
to participate in screening sent
Patient characteristics and set-
ting
985 participants (total population not reported)
Participant characteristics are reported across both studies
Age: 40 years or over
Sex: 892 male 1135 female
SES: Not stated
Ethnicity: Not stated
Stated risk factors: 162 heavy smoker 608 moderate smoker 1257 non-smoker; 61 heavy drinker
527 moderate drinker 1439 light drinker
Previous history: Not stated
Location: UK
Clinical setting: Inner city medical practice
Index tests Index test: Thorough visual examination of the surface of the oral mucosa according to the British
Postraduate Medical Federation, 1991, by either a general dental practitioner, a community dental
officer or a junior hospital dentist (24 screeners)
Description of positive case definition by index test as reported: “A lesion was defined as positive
when a white patch, red patch, or an ulcer of longer than two weeks duration was detected.” “The
screeners were also instructed to include lesions of lupus erythematosus, submucous fibrosis or
actinic keratosis as positive.” All types of lichen planus were also regarded as positive
Sequence of tests: Index followed by reference
Training or calibration: “..screeners advised of diagnostic criteria which should result in a positive
or negative screen .....no formal training or standardisation was undertaken”
Blinding of examiners: Index test completed before reference
Conflict of interests: Supported by grant from the Department of Health, UK
Target condition and reference
standard(s)
Target condition: Oral cancer and pre-cancer
Reference standard: Visual examination by second dental specialist who was able to refer subjects
for further tests or review as appropriate (single specialist)
Description of positive case definition by reference test as reported: As for index test. “A lesion was
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defined as positive when a white patch, red patch, or an ulcer of longer than two weeks duration was
detected.” “The screeners were also instructed to include lesions of lupus erythematosus, submucous
fibrosis or actinic keratosis as positive.” All types of lichen planus were also regarded as positive
Training or calibration: Not stated but quoted as “a specialist”. Single examiner so no calibration
Blinding of examiners: Index test completed before reference. “The results were also recorded on
a standard form which was collated with the screeners’ form only after completion.” “All subjects
were examined by a specialist who provided an independent definitive diagnosis”
Prevalence of the target condition on the sample: 22/985 2.2%
Flow and timing Time interval and any interventions between index test(s) and reference standard: Not explicit,
however, reasonable to assume both conducted on same visit
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: None
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
38Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Julien 1995a (Continued)
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Mathew 1997
Study characteristics
Patient sampling Methodof patient selection: Re-examinationof 2069 eligible participants from the 9000 participants
recruited in January toMay 1996, shortly after commencement of the study. “Subjects were selected
by choosing densely inhabited areas to allow re-examination of as many subjects as possible in two
weeks.” Study looking at the reproducibility and validity of oral visual inspection by health workers
within a randomised controlled intervention trial of visual screening
Patient characteristics and set-
ting
2069 participants
Age: Mean 47.7 years, sd 9.1 years (range 35 to 64 years)
Sex: 678 males; 1391 females
SES: Recorded but not reported
Ethnicity: Recorded but not reported
Stated risk factors: Details on smoking and alcohol were recorded but not reported
Previous history: Recorded but not reported
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Location: Kerala, India
Clinical setting: Participants’ homes
Index tests Index test: Systematic oral visual examination by trained health workers (n = 14) in the inspection
and detection of oral lesions
Description of positive case definition by index test as reported: “...homogeneous leucoplakia, ul-
cerated leucoplakia, verrucous leucoplakia, erythroplakia, nodular leukoplakia, submucous fibrosis,
and oral cancer”
Sequence of tests: Initial screen by health worker followed by second screen (the index test) by same
health worker (1 to 6 months later) to establish reliability. 2069 received the index test (second
screen by HW) and this formed the sample for the sensitivity and specificity calculations
Training or calibration: “Training sessions spread over 6 weeks composed of lectures, practical
demonstrations and field work conducted by Faculty... At the end of training sessions written and
practical tests were conducted identifying the best health workers.... They were also given manuals
and photographic documentation to identify different types of oral lesions.” The “best performing”
health workers were retained for the study
Blinding of examiners: Index test completed before reference
Conflict of interests: Supported by a grant from the Association of International Cancer Research,
Scotland, UK
Target condition and reference
standard(s)
Target condition: As for index test “...homogoneous leukoplakia, ulcerated leukoplakia, verrucous
leukoplakia, erythroplakia, nodular leukoplakia, submucous fibrosis, and oral cancer”
Reference standard: Visual examination by a specialist physician (decision made by single physician,
1 of 3). “....comparison with pathological findings is not possible as biopsy has not been performed
for most case. Biopsy is performed for cases of nodular leucoplakias, erythroplakias and suspicious
growths only, and this is currently being undertaken”
Training or calibration: 100 participants formed the basis of comparability of findings evaluation.
Kappa value of 0.85 was reported for the findings of the 3 physicians
Blinding of examiners: Reference test undertaken immediately after index test. Both health worker
and specialist in participants’ home at the same visit
Prevalence of the target condition on the sample: 212/2069 10.3%
Flow and timing Time interval and any interventions between index test(s) and reference standard: “This was imme-
diately followed by an independent examination of the same subject by one of three physicians”
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: None
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Were all patients included in the
analysis?
Yes
Low
Mehta 1986
Study characteristics
Patient sampling Method of patient selection: For the screening study, a basic health worker visited each household to
report on health status in an area of high oral cancer prevalence. “Four adjacent blocks, two as study
area I (pop 218728) and two as study area II (pop 250,399) were selected for this investigation.”
Field checking of the diagnosis of the health worker by the study dentist was initiated after 6months
and completed for 40 health workers. For each of the health workers’ lists “A house with a lesion
case was selected as a nodal point and all the available individuals from nearby houses who figured
in the list were examined.” Carried out on high risk individuals within a household “..i.e. people
aged 35 years and above with tobacco habits”
Patient characteristics and set-
ting
2063 ’high risk’ participants (out of 39,331 screened)
Age: 35 years and above
Sex: Not stated
SES: Not stated
Ethnicity: Not stated
Stated risk factors: All participants had tobacco habits, HPV and alcohol use not reported
Previous history: Not stated
Location: Kerala, India
Clinical setting: Participants’ homes
Index tests Index test: Standard visual examination by basic health worker working to a reference manual
Description of positive case definition by index test as reported: Referable lesions were “nodular
leukoplakia, submucous fibrosis, and ulcers and growths suggestive of oral cancer.” Non-referable
lesions included “homogenous leukoplakia, oral lichen planus, smoker’s palate and central papillary
atrophy of the tongue papillae.” Definition of positive threshold may over-estimate accuracy values
(homogenous leukoplakia considered to be test negative)
Sequence of tests: Index followed by reference
Training or calibration: Yes. Training provided by dentists, members of the research team. “The
final performance of the trainees was judged as satisfactory”
Blinding of examiners: Index test completed before reference
Conflict of interests: None stated. Study was supported by a grant from the National Institutes of
Health
Target condition and reference
standard(s)
Target condition: Referable lesion
Reference standard: Standard visual examination by dentist (member of research team) in partici-
pants’ home
Description of positive case definition by reference test as reported: Referable lesions were “nodular
leukoplakia, submucous fibrosis, and ulcers and growths suggestive of oral cancer.” Non-referable
lesions included “homogenous leukoplakia, oral lichen planus, smoker’s palate and central papillary
atrophy of the tongue papillae.” Definition of positive threshold may over-estimate accuracy values
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(homogenous leukoplakia considered to be test negative)
Training or calibration: The research team of dentists “...was experienced in conducting house to
house surveys for oral cancer and precancerous lesions in rural areas of Ernakulam district for 16
years”
Blinding of examiners: Unclear whether the dentists were aware of the screening results. “The list
contained the categorization indicated by the BHW”
Prevalence of the target condition on the sample: 27/1921 1.41%
Flow and timing Time interval and any interventions between index test(s) and reference standard: At the same visit.
“One day was devoted to rechecking for each of the 40 BHW”
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: 142 were falsely reported to have been examined by the BHW,
and they were excluded from further analysis. Exclusions are unlikely to induce bias
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
Comparative
Notes Data presented for field check only, not full screening programme
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
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out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Low
Scott 2010
Study characteristics
Patient sampling Method of patient selection: “Participants were recruited from a general practitioner’s list in South
East London, UK. Patients who were at risk of oral cancer (aged 45 years or older and who smoked)
were identified as potential participants by their general practitioner.” Recruitment was by invitation
letter to 243 eligible patients. 53 patients participated
Patient characteristics and set-
ting
53/243 eligible patients
Age: Mean age 54 years (sd 5.9 years, range 45 to 64 years)
Sex: 36 male 17 female
SES: 24 no/compulsory education; 25 beyond compulsory education
Ethnicity: 37 white 14 other
Stated risk factors: 40 hazardous drinking (AUDIT-C) 11 alcohol dependent; 41 current smoker
12 used to smoke; 27 regular attenders, 10 irregular attenders, 15 emergency or never
Previous history: Not stated
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Location: South East London, UK
Clinical setting: “Research room”
Index tests Index test: Mouth self examination in accordance with a patient leaflet, at the same location. “The
leaflet had been specifically developed for and piloted with heavy smokers and drinkers and has a
reading age of 10 to 12 years and a Flesch reading ease score of 79%, indicating it can be read and
understood with ease”
Description of positive case definition by index test as reported: Red patches, white patches, ulcers
and lumps or swellings
Sequence of tests: Reference followed by index
Training or calibration:Conductedmouth self examination in accordancewith specifically developed
patient leaflet
Blinding of examiners: Reference preceded index test. “After the dentist’s examination (yet before
the results of the examination were revealed to the participant)...” “The dentist remained in the
room but did not assist the participant in conducting the mouth self examination”
Conflict of interests: The study was funded by a Cancer Research UK Pilot Project Award (C19770/
A8554), but no conflict of interest
Target condition and reference
standard(s)
Target condition: Red patches, white patches, ulcers and lumps or swelling
Reference standard: Examination by single dentist (member of research team). Protocol for exami-
nation reported
Description of positive case definition by reference test as reported: “The presence (including site
and provisional diagnosis) and absence of potentially malignant oral lesions (ulcers, white or red
patches, or lumps/swellings) were noted on a pro forma”
Training or calibration: Experience and training not reported
Blinding of examiners: Yes. Reference standard proceeded index test
Prevalence of the target condition on the sample: 12/53 22.6%
Flow and timing Time interval and any interventions between index test(s) and reference standard: Reference test
immediately followed index test
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: None
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
Comparative
Notes Low response rate for participation 53/243 eligible patients recruited from an “at risk” group
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Low
Su 2010
Study characteristics
Patient sampling Method of patient selection: Community-based randomised controlled trial of Toluidine blue for the
detection and incidence of oral cancer. Mass screening programme (eligible at 15 years old or over)
aimed at detecting 5 prevalent neoplasms (cervical, breast, hepatocellular, colorectal, and oral cancer)
and 3 chronic diseases (hypertension, diabetes, and hyperlipidaemia). From the mass screening
programme individuals were ineligible for the randomised controlled trial if they “lacked oral habits
such as cigarette smoking or chewing betel quid.” Randomised to either visual examination plus
Toluidine blue (experimental group) or to visual examination alone (control group)
Patient characteristics and set-
ting
Analysis of data of 7975 participants enrolled into the randomised controlled trial during 2000
Age: Mean 44.9 years sd 14.4; mean 44.6 years sd 15.3
Sex: Male 3719 and 3550; female 361 and 345
SES: Not stated
Ethnicity: Not specified
Stated risk factors: Participants were smokers or betel quid chewers, HPV or alcohol consumption
not reported
Previous history: Not stated
Location: Taiwan
Clinical setting: Randomised controlled trial as part of community-based screening programme
Index tests Target condition: Asymptomatic oral pre-malignant lesions (OPML) and oral cancer. Oral sub-
mucous fibrosis, homogenous leukoplakia, non-homogeneous leukoplakia, erythroplakia and oral
cancer
Index test (2):
Visual examination by dentist plus Toluidine blue (experimental group)
Visual examination by dentist alone (control group)
Description of positive case definition by index test as reported: “The presence of any visible lesion
in the oral cavity was recorded as screen-positive.” Information reported for screen positive rate and
detection rate
Sequence of tests: Index test followed by reference standard
Training or calibration: Training given to dentists was carried out by a senior oral pathologist. No
calibration was reported
Blinding of examiners: Index test followed by reference standard. Placebo dye
Conflict of interests: None declared
Target condition and reference
standard(s)
Target condition: Any visible lesion (detection), oral cancer (incidence rate of oral cancer, diagnostic
accuracy)
Reference standard: Only screened positives referred for biopsy; entire cohort (screened positive or
screened negative) assessed through national cancer registry
Description of positive case definition by reference test as reported: As indicated by national cancer
registry
Training or calibration: “Diagnostic criteria, examination procedures, and documentation formats
were discussed, taught, and calibrated in advance for all personnel participating in the study”
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Blinding of examiners: All personnel were unaware of group allocation
Prevalence of the target condition on the sample: 0.12% and 0.15% in each trial arm
Flow and timing Time interval and any interventions between index test(s) and reference standard: Screened positive
participants were referred for a definite clinical diagnosis within 10 to 14 days. 5-year follow-up of
oral cancer development through linkage to the national cancer registry
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: None
Characteristics and proportion of individuals who received a reference standard other than exam-
ination and clinical evaluation by a specialist physician: All. Quote: “We retrieved the occurrence
of oral cancer, survival status, and causes of death of the studied participants by linking the entire
cohort with the National Cancer Registry and the National Household Registry until December
31, 2004”
Comparative
Notes Estimates of sensitivity and specificity of the index tests are based on the outcome of oral cancer
as indicated by the national cancer registry. Results presented for detection rate ratio for oral pre-
malignant lesions and malignant lesions and incidence rate of oral cancer
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
48Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Su 2010 (Continued)
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
Low
Sweeny 2011
Study characteristics
Patient sampling Method of patient selection: “...a prospective study was performed at the University of Alabama at
Birmingham. Consecutive patients who presented to the Otolaryngology clinic between November
2009 and October 2010 for follow-up (n = 88) following management of primary head and neck
cancer”
Patient characteristics and set-
ting
88 participants
Age: Mean 64 years (range 41 to 85 years)
Sex: 65 male 23 female
SES: Not reported
Ethnicity: 54 Caucasian
Stated risk factors: 58 alcohol consumption; 71 history of tobacco use
Previous history: “All patients had undergone a previous treatment for head and neck cancer.” “All
patients evaluated during routine surveillance visits”
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Location: Alabama, USA
Clinical setting: Otolaryngology clinic
Index tests Index test (3): “..sites were initially screened by a registered nurse and then by a fellowship trained
head and neck surgeon using visualization with white light illumination (traditional exam light)
followed by visualization of tissue autofluorescence and tissue reflectance. The Trimira® Identafi®
3000 ultra, multi-spectral oral cavity screening system was used.” “Patients were evaluated by direct
visualization of the oral cavity with white light (traditional exam light), tissue autofluorescence and
tissue reflectance.” Only the results of visualisation examination with white light are included in this
analysis as the autofluorescence and reflectance data are not presented as adjuncts but as independent
tests
Description of positive case definition by index test as reported: “oral cavity cancer.” Abnormality/
lesion with concern for malignancy or recurrence. Not explicitly stated
Sequence of tests: Index followed by reference
Training or calibration: Not stated but index test conducted by registered nurse followed by head
and neck surgeon
Blinding of examiners: Not stated but index tests preceded reference test. No information of blinding
after successive index tests
Conflict of interests: This work was supported by a grant from the National Institute of Health
(2T32 CA091078-09), but no conflict of interest
Target condition and reference
standard(s)
Target condition: Head and neck cancer recurrence
Reference standard: “Screening results were compared to histological biopsy results or a three month
follow-up screening. Any area of abnormality found by visualization with traditional white light
illumination and/or by tissue autofluorescence or reflectance was biopsied and evaluated by a pathol-
ogist using standard histopathologic analysis”
Description of positive case definition by reference test as reported: “Positive disease”
Training or calibration: Not stated
Blinding of examiners: Not stated
Prevalence of the target condition on the sample: 4/88 4.6%
Flow and timing Time interval and any interventions between index test(s) and reference standard: Not explicitly
stated. Follow-up screening visit at 3 months
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: None
Characteristics and proportion of individuals who received a reference standard other than exam-
ination and clinical evaluation by a specialist physician: Biopsy for screened positive participants.
Reference standard by follow-up visit for some participants (number of participants not specified)
Comparative
Notes “Our study was unique in that it evaluated the population most likely to benefit from screening.”
Participants attending for routine surveillance
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
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Were all patients included in the
analysis?
Yes
Unclear
Warnakulasuriya 1990
Study characteristics
Patient sampling Method of patient selection: Screening programme at a rural location, Kadugannawa, Sri Lanka.
“The PHCworkers carried out an examination….of people over the age of 20 years in their area;….
voters lists were used to identify and record the persons examined and those who were referred”
Patient characteristics and set-
ting
Population of 87,277 adults (> 20 years of age) of whom 29,295 were screened during study periods
of 52 weeks. From this number 1872 received both the index test and the reference test. Patient
characteristic information reported only for those screened positive and attending the referral centre
Age: 20 to 39 years n = 182, 40 to 59 years n = 315, > 60 n = 163
Sex: 480 male 180 female
SES: Not stated
Ethnicity: Not stated
Stated risk factors: Not stated
Previous history: Not stated
Location: Sri Lanka
Clinical setting: Participants’ own homes
Index tests Index test: Examination of the lining mucosa of the oral cavity in natural daylight using dental
mirrors by primary health care (PHC) workers comprising midwives, public health inspectors and
public health nurses
Description of positive case definition by index test as reported: “The PHC workers identified
positive cases on the basis of simple, explicitly stated criteria. The diagnosis criteria included the
presence of a white or red lesion on the oral mucosa with a smooth, corrugated or nodular surface
which cannot be scraped of using the dental mirror head. Elevated and ulcerated areas with co-
existing red or white lesions were also referable”
Sequence of tests: Index followed by reference
Training or calibration: “...participated in a two-day training programme which provided a clinical
demonstration of oral cancer and precancer, instructions regarding the screening methods and
referral mechanisms”
Blinding of examiners: Index test preceded reference test
Conflict of interests: Authors declare no conflict of interest. Work was supported by the Cancer
Control Programme of Sri Lanka
Target condition and reference
standard(s)
Target condition: Oral cancer/pre-cancer (for purposes of accuracy of examination). Leukoplakia,
erythroplakia or carcinoma
Reference standard: Re-examination by the project dentist
Description of positive case definition by reference test as reported: Oral cavity cancer
Training or calibration: Not stated but carried out by experienced dentists
Blinding of examiners: Unclear. Re-examination of screened positive cases took place at the referral
centre “(all screened positives were referred); a sample of screened negative participants were ran-
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domly selected from PHC files by the project dentist visiting each field area”
Prevalence of the target condition on the sample: 405/1872 21.6% (sample for diagnostic test
accuracy assessment), 660/29,295 screened positive referable lesions 2.25%
Flow and timing Time interval and any interventions between index test(s) and reference standard: Re-examination
of “660 cases who arrived at the referral centre within 18 months (January 1981 to June 1982) after
case detection.” “...negative cases randomly selected from PHC files.. were re-examined, during the
three month period of initial PHC examinations”
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: 87,277 adults were eligible for the screening programme of
whom 29,295 were screened. “All referred (screened positive) participants who arrived at the referral
centre were re-examined by the project dentist to validate the PHC diagnosis.” “A sample of negative
cases was randomly selected from PHC files (in whom PHCworkers had not recorded a lesion) were
re-examined, during the three month period of initial examination. Aminimum of 30 negative cases
from each PHC file were thus re-examined.” 1872 received both the index test and the reference
test
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
Comparative
Notes Only 660 screened positive participants arrived at the referral centre within 18 months after screen
positive detection; 54.1% of detected cases in the field
Index test target condition “white or red lesion that cannot be scraped off”; reference standard for
accuracy of screening “correctly referred cases who, on examination, had oral cancer or precancer”
Prevalence in sample for diagnostic test accuracy assessment was high 21.6%
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Warnakulasuriya 1991
Study characteristics
Patient sampling Method of patient selection: Optional screening programme at a rural location, Galle, Sri Lanka.
Primary health care (PHC) workers carried out a visual oral examination of people over the age of
20 years in their geographical area. The 1981 electoral list was used to identify eligible individuals
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Patient characteristics and set-
ting
Population of 72,867 adults (> 20 years of age) of whom 57,124 were examined during 1 year by
PHC workers. From this number 3543 received both the index test and the reference test
Age: Participants were 20 years of age or older
Sex: Not stated
SES: Not stated
Ethnicity: Not stated
Stated risk factors: Not stated
Previous history: Not stated
Location: Sri Lanka
Clinical setting: Participants’ own homes
Index tests Index test: Examination of the lining mucosa of the oral cavity in natural daylight using dental
mirrors by PHC workers
Description of positive case definition by index test as reported: “The PHC workers identified
positive cases on the basis of simple, explicitly stated criteria. The diagnosis criteria included the
presence of a white or red lesion on the oral mucosa with a smooth, corrugated or nodular surface
which cannot be scraped of using the dental mirror head. Elevated and ulcerated areas with co-
existing red or white lesions were also referable”
Sequence of tests: Index test followed by reference test
Training or calibration: Participated in a 2-day trainingprogrammewhich provided a clinical demon-
stration of oral cancer and pre-cancer, instructions regarding the screening methods and referral
mechanisms, as in the pilot study (Warnakulasuriya 1990)
Blinding of examiners: Index test followed by reference test
Conflict of interests: Authors declare no conflict of interest. Work was supported by funds from the
National Cancer Control Programme of Sri Lanka
Target condition and reference
standard(s)
Target condition: Oral cancer/pre-cancer (for purposes of accuracy of examination)
Reference standard: Re-examination by the project dentist. “The hospital dental surgeon reexamined
all referred subjects to revalidate the diagnosis given by the PHCW.” “Biopsies were obtained from
all cases suggestive of oral cancer and a representative sample of precancers was also made by incision
biopsy”
Description of positive case definition by reference test as reported: Oral cavity cancer
Training or calibration: “A hospital dentist attached to a local hospital and who had received special
training in oral cavity examinations was assigned to supervise the project”
Blinding of examiners: Unclear. Re-examination of screened positive cases took place at the referral
centre (all screened positives were referred); a sample of screened negative participants were randomly
selected from PHC files by the project dentist visiting each field area
Prevalence of the target condition on the sample: 1797/3543 50.7% (sample for diagnostic test
accuracy assessment); 3559/57,124 6.23% screened positive (oral lesions)
Flow and timing Time interval and any interventions between index test(s) and reference standard: Not stated
Characteristics and proportion of individuals who did not receive the index test(s) and/or reference
standard or excluded from analysis: 72,867 adults were eligible for the screening programme of
whom 57,124 were screened. Re-examination of 2193 participants who arrived at the referral centre
out of 3559 who screened positive. Field checking of 1350 screened negative cases was undertaken
(random sample from electoral list). 21 excluded from analysis due to non-diagnosis from PCH
worker. 3543 participants received both the index test and the reference test
Characteristics and proportion of individuals who received a reference standard other than exami-
nation and clinical evaluation by a specialist physician: None
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Warnakulasuriya 1991 (Continued)
Comparative
Notes Only 2193 screened positive participants arrived at the referral centre; 62% of detected cases in the
field
Prevalence in sample for diagnostic test accuracy assessment was very high 50.7%
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was conflict of interest avoided? Yes
Wheremultiple index testswere
used, were the results of the sec-
ond index test interpreted with-
out knowledge of the results of
the first index test?
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Warnakulasuriya 1991 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
HPV = human papillomavirus; sd = standard deviation; SES = socio-economic status
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bhalang 2008 Patients suspected of oral squamous cell carcinoma
Bowles 1973 Patients suspected of cancer
Chen 2007 Presenting with lesions
Csépe 2007 Prevalence data and risk factors
Fernández Garrote 1995 Data on referral, incidence and stage
Hapner 2011 Prevalence data
Huber 2004 Exploration of oral soft tissue under chemiluminescent illumination
Huff 2009 Inappropriate study design
Leocata 2007 Prevalence data
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(Continued)
Lim 2003 Prevalence data
Nagao 2000 Participation rates and prevalence data; no screen negatives verified
Oh 2007 Outcomes measured on a lesion level. Cross-tabulation table cannot be constructed
Poh 2007 Prevalence data
Srivasta 1971 Chronic ulcerative lesions
Vahidy 1972 Presenting with lesions
Warnakulasuriya 2010 Prevalence data
Characteristics of ongoing studies [ordered by study ID]
Kulak 2010
Trial name or title The use of autofluorescence in detection of oral lesions
Target condition and reference standard(s) Oral lesions
Head and neck examination under standard light
Index and comparator tests Fiberoptic examination
VELscope exam
Starting date Not stated. Publication in 2010 with results for 17/300 participants required
Contact information Jessica Kulak, jkulak2@med.miami.edu
Notes
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Conventional oral examination 10 25568
2 Mouth self examination 2 34819
Test 1. Conventional oral examination.
Review: Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
Test: 1 Conventional oral examination
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chang 2011 282 172 3 13149 0.99 [ 0.97, 1.00 ] 0.99 [ 0.99, 0.99 ]
Downer 1995 12 2 5 290 0.71 [ 0.44, 0.90 ] 0.99 [ 0.98, 1.00 ]
Ikeda 1995 9 9 6 130 0.60 [ 0.32, 0.84 ] 0.94 [ 0.88, 0.97 ]
Julien 1995 14 8 8 955 0.64 [ 0.41, 0.83 ] 0.99 [ 0.98, 1.00 ]
Julien 1995a 26 12 6 998 0.81 [ 0.64, 0.93 ] 0.99 [ 0.98, 0.99 ]
Mathew 1997 200 31 12 1826 0.94 [ 0.90, 0.97 ] 0.98 [ 0.98, 0.99 ]
Mehta 1986 16 35 11 1859 0.59 [ 0.39, 0.78 ] 0.98 [ 0.97, 0.99 ]
Sweeny 2011 2 2 2 82 0.50 [ 0.07, 0.93 ] 0.98 [ 0.92, 1.00 ]
Warnakulasuriya 1990 384 276 21 1191 0.95 [ 0.92, 0.97 ] 0.81 [ 0.79, 0.83 ]
Warnakulasuriya 1991 1741 431 52 1298 0.97 [ 0.96, 0.98 ] 0.75 [ 0.73, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Mouth self examination.
Review: Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults
Test: 2 Mouth self examination
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Elango 2011 39 15 180 34532 0.18 [ 0.13, 0.24 ] 1.00 [ 1.00, 1.00 ]
Scott 2010 4 19 8 22 0.33 [ 0.10, 0.65 ] 0.54 [ 0.37, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Screening tests for PMDs and oral cavity cancer
Test Characteristics Classification of response Other information
Conventional oral examination
(COE)
A standard visual and tactile
examination of the oral mu-
cosa under normal (incandes-
cent) light
The presence of an oral mu-
cosal abnormality is classified as
a positive test result; the absence
of any oral mucosal abnormali-
ties is classified as a negative test
result
Traditionally been used as an
oral cancer screen, but its utility
is debated (Lingen 2008)
Advantages: quick and easy
once trained, minimally inva-
sive
Disadvantages: oral mucosal
abnormalities are not necessar-
ily clinically or biologically ma-
lignant; only a small percent-
age of leukoplakias are pro-
gressive or become malignant;
COE cannot distinguish be-
tween those that are or are
not; some pre-cancerous lesions
may exist within oral mucosa
that appears clinically normal
by COE alone (Lingen 2008)
Vital rinsing (e.g. Toluidine
blue, Tolonium chloride)
Vital rinsing refers to the use of
dyes such as Toluidine blue or
Tolonium chloride to stain oral
mucosa tissues for PMD orma-
lignancy (Leston 2010; Lingen
2008; Patton 2008). The pro-
cedure is as follows
• Pre-rinse with acetic acid
• Rinse with water
The result of the test is classified
as positive if tissue is stained and
negative if no tissue is stained,
or equivocal if no definitive re-
sult can be obtained
Advantages: ability to define
areas that could bemalignant or
abnormal but cannot be seen;
assess the extent of the PMDfor
excision
Disadvantages: benign inflam-
matory lesions subject to stain;
failure of some cancerous le-
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Table 1. Screening tests for PMDs and oral cavity cancer (Continued)
• Apply Toluidine blue
• Post-rinse with acetic acid
• Rinse with water
• Observe mucosa to check
for staining
sions to stain; variation in
test performance depending on
how thorough the test proce-
dures are followed; contraindi-
cated in those who are known
to be allergic to iodine
Light-based detection (e.g.
ViziLite and ViziLite plus, Mi-
crolux/DL, VELscope, Identafi
3000)
Light-based systems to identify
pre-malignant and malignant
lesions and to highlight their
presence through tissue autoflu-
orescence or reflectance (Leston
2010; Lingen 2008; Patton
2008). E.g. using ViziLite Plus
or Microlux/DL, the procedure
is as follows (Lingen 2008)
• Pre-rinse with acetic acid
• Use blue-light source to
visually assess the oral cavity
ViziLite Plus also provides
a tolonium chloride solution
(TBlue) to aid in the marking
of the lesion for biopsy once the
light source is removed
The result of the test is classed
as negative if the appearance of
the epithelium is lightly bluish
white and positive if the appear-
ance of the epithelium is dis-
tinctly white (acetowhite)
For systems based on autoflu-
orescence the result of the test
is classed as negative if fluores-
cence is maintained and posi-
tive if fluorescence is lost
Advantages: simple to use;
non-invasive; do not require
consumable re-agents; provide
real time results; can be per-
formed by a wide range of op-
erators after a short training pe-
riod
Disadvantages: the necessity of
a dark environment; high ini-
tial set up (for VELscope) or
recurrent costs (for ViziLite in
low-income countries); lack of
permanent record unless pho-
tographed; inability to objec-
tively measure visualisation re-
sults
Mouth self examination Self examination, usually in
the home setting in accordance
with instructional material
Usually the presence of any le-
sion
Advantages: simple to carry out
and low cost. Can be carried out
in an individual’s own home
Disadvantages: target condi-
tion is the presence or absence
of oral lesions. Cannot differen-
tiate between potentially malig-
nant and non-malignant lesions
Blood and saliva analyses These novel technologies are at
an early stage of development
and evaluation
Analysis of blood or saliva sam-
ples which tests for the presence
of bio-markers of PMD and
oral cancer (Brinkmann 2011;
Lee 2009; Li 2006)
Cut-off probabilities
vary widely and are dependent
on the individual bio-marker or
combination of bio-markers ex-
amined
Molecular markers for diagno-
sis include changes in cellu-
lar DNA, altered mRNA tran-
scripts, altered protein levels
Advantages: non-invasive
(saliva tests) or minimally inva-
sive (blood tests)
Disadvantages: there is a ten-
dency for the estimated diag-
nostic accuracy of new health
technologies to decline over
time as evidence from inde-
pendent evaluations accumu-
late (Wyatt 1995). This bias,
which can be substantial, has
been demonstrated in other
domains, e.g. acute abdomi-
nal pain (Liu 2006) and clin-
ical decision support systems
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Table 1. Screening tests for PMDs and oral cavity cancer (Continued)
(Garg 2005). Promising bio-
marker tests in several clini-
cal areas were eventually been
shown to be disappointing (
Buchen 2011). It remains to be
seen whether this is the case
with oral cancer and PMDs
PMDs = potentially malignant disorders
Table 2. Indicators for the assessment of methodological quality
Domain Patient selection Index test Reference standard Flow and timing
Description Describe methods of pa-
tient selection. Describe
included patients (char-
acteristics, prior
testing, presentation, in-
tended use of index test
and setting)
Describe the index test
and how it was con-
ducted and interpreted.
Describe the sequence of
tests, any training or cal-
ibration of assessors (lev-
els of agreement should
be reported. Where this
is measured by the kappa
statistic*, acceptable val-
ues
range from 0.61 (mod-
erate agreement) to 1.
00 (almost perfect agree-
ment) (Landis 1977)),
any procedures taken to
ensure blinding of ex-
aminers, post-hoc or a
priori threshold specifi-
cation, any conflict of
interest or commercial
funding
*This statistic is a mea-
sure of inter-rater agree-
ment of observations
measured at a categorical
level
Describe the reference
standard and how it
was conducted and in-
terpreted. Any measures
taken to ensure assessors
were blinded to the re-
sults of the index tests
should be documented,
along with the sequence
of reference and index
tests
Describe the character-
istics and proportion of
patients who did not
receive the index test
(s) and/or reference stan-
dard, who received a
reference standard other
than examination and
clinical evaluation by a
specialist physician, or
who were excluded from
the 2 x 2 table (refer
to flow diagram). De-
scribe the time inter-
val and any interven-
tions between index test
(s) and reference stan-
dard. The length of time
between the index test
and reference standard
should be short in the
majority of cases. If the
period elapsed between
initial screening and ref-
erence standard (exami-
nation and clinical eval-
uation) is greater than 6
weeks then this was con-
sidered an unacceptable
delay
Signalling questions
(Yes/No/Unclear)
Was a consecutive or ran-
dom sample of patients
Were the index test re-
sults interpreted without
Is the reference standard
likely to correctly clas-
Was there an appropri-
ate time interval between
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Table 2. Indicators for the assessment of methodological quality (Continued)
enrolled?
Classify as Yes if consec-
utive patients or a ran-
dom sample of individu-
als were recruited
Classify as No if non-
consecutive patients or
a non-random sample
of individuals were re-
cruited
Classify asUnclear if pa-
tient selection was not
clearly described
knowledge of the results
of the reference stan-
dard?
Classify as Yes if inter-
preters of index test re-
sults clearly do not know
results of reference stan-
dard
Classify as No if inter-
preters of index test re-
sults clearly know results
of reference standard
Classify
as Unclear if study did
not provide any infor-
mation on whether in-
terpreters of index tests
were blinded to reference
standard
sify the target condition?
The reference standard
is an examination and
clinical evaluation by a
physician with special-
ist knowledge which if
stated as such should be
acceptable. Ideally this
should be undertaken
independently by more
than one specialist. Al-
ternatively an acceptable
reference standard is ex-
tended follow-up
Classify as Yes if the
test is examination and
clinical evaluation by a
physician with specialist
knowledge and/or train-
ing, or a non-specialist
with dedicated training
to an acceptable standard
Classify as No if the test
result is examination and
clinical evaluation by a
non-specialist physician
in the absence of dedi-
cated training
Classify asUnclear if the
study does not report the
experience and training
of those carrying out the
reference standard
the index test(s) and ref-
erence standard?
Classify as Yes if the
delay between the in-
dex test(s) and reference
standard is considered
acceptable for themajor-
ity of participants
Classify asNo if the delay
between the index test(s)
and reference standard is
considered unacceptable
for the majority of par-
ticipants
Classify asUnclear if the
delay between the in-
dex test(s) and reference
standard is not explicitly
stated
Did the study avoid in-
appropriate exclusions?
Classify as Yes if the sam-
ple consisted of appar-
ently healthy individuals
Classify as No if only
individuals with existing
PMDs were recruited
Classify as Unclear if ex-
clusions were not clearly
described
If a threshold was used,
was it pre-specified?
Classify as Yes if the
threshold was pre-speci-
fied
Classify as No if the
threshold was not pre-
specified
Classify as Unclear if it
is unclear whether the
threshold was pre-speci-
fied
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Classify as Yes if person-
nel clearly do not know
index test results when
performing the examina-
tion and clinical evalu-
ation or evaluating fol-
low-up data
Classify as No if per-
sonnel clearly know in-
dex test results when per-
Did all patients receive
the same reference stan-
dard?
Classify asYes if the same
reference standard was
used in all participants
Classify asNo if the same
reference standard was
not used in all partici-
pants
Classify as Unclear if it
is unclear whether differ-
ent reference standards
were used
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Table 2. Indicators for the assessment of methodological quality (Continued)
forming the examination
and clinical evaluation
or evaluating follow-up
data
Classify
as Unclear if study did
not provide any informa-
tion on whether person-
nel were blinded to the
index test results
Where multiple index
tests were used, were the
results of the second in-
dex test interpretedwith-
out knowledge of the re-
sults of the first index
test?
Classify as Yes if index
test results were inter-
preted without knowl-
edge
Classify as No if the
index test results were
interpreted with knowl-
edge
Classify as Unclear if it
is unclear whether the re-
sults of the second in-
dex test were interpreted
without knowledge of
the results of the first in-
dex test
Were all patients in-
cluded in the analysis?
Classify as Yes if all pa-
tients were included in
the analysis
Classify as No if only
some patients were in-
cluded in the analysis
Classify as Unclear if it
is unclear whether all pa-
tients were included in
the analysis
Were any conflicts of in-
terest stated?
Classify as Yes if the
study declared no con-
flict of interest
Classify as No if the
study declared a conflict
of interest
Classify as Unclear if
therewas no information
on conflict of interest
Risk of bias: High/Low/
Unclear
Could the selection of
individuals have intro-
duced bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
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Table 2. Indicators for the assessment of methodological quality (Continued)
Concerns regard-
ing applicability: High/
Low/Unclear
Are there concerns that
the included individuals
do not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
Assessment of overall risk of bias and applicability
An overall judgement of risk of bias and applicability to the review (high, low or unclear) was undertaken based on the judgements
given to each domain. If the answers to all signalling questions within a domain were judged as yes indicating low risk of bias, then
the domain was judged to be at low risk of bias. A no response to a signalling question was taken as an indication of the potential for
risk of bias and the authors considered this risk within the context of the study before making a decision on whether the study was a
high/low risk of bias for that domain
If any of the 4 domains was judged to be at high risk of bias then the study was judged to have a high risk of bias overall. If any of
the 3 applicability domains was judged to be at high concern regarding applicability then the study was judged to be of high concern
regarding applicability overall
PMDs = potentially malignant disorders.
A P P E N D I C E S
Appendix 1. Search strategies for the electronic databases
Cochrane Diagnostic Test Accuracy Register search strategy
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*)
Cochrane Oral Health Group’s Trials Register search strategy
An updated search of the Cochrane Oral Health Group’s Trials Register was conducted 30 April 2013 using the Cochrane Register of
Studies software and the search strategy below:
#1 ((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or
cheek* or intra-oral* or intraoral* or gum or gums or labial*):ti,ab) AND (INREGISTER)
#2 ((tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas* or malignan* or metasta* or dysplas* or lesion* or ulcer* or
precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus” or leukoplakia or “submucous fibrosis” or “actinic keratosis”
or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or hyperplas* or hyperkerato*):ti,ab) AND (INREGISTER)
#3 ((cytodiagnosis or cytophotometry or “brush biops*” or “oral cdx” or oralcdx or “modified liquid based cytology” or “exfoliat*
cytolog*” or “tolonium chloride” or “toludine b*” or “toluidine b*” or tblue or t-blue or “toludine dye*” or “toludine rins*” or “toludine
stain*” or “toludine wash*” or “toluidine dye*” or “toluidine rins*” or “toluidine stain*” or “toluidine wash*” or luminescence or
fluorescen* or “light emitting diode*”):ti,ab) AND (INREGISTER)
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#4 (((blood or saliva) AND (analys* or inspect* or test or examin*)):ti,ab) AND (INREGISTER)
#5 ((“blue spectrum” or LED or luminous or “visual* adjunct*” or vizilite or microlux* or orascoptic or velscope or lumenoscope* or
autofluorescen* or chemilumiescen* or spectrophotometr* or “acetic acid” or acetowhite or “tumor marker*” or “tumour marker*” or
“neoplas* marker*”):ti,ab) AND (INREGISTER)
#6 ((diagnos* AND (exam* or histolog* or check* or screen*)):ti,ab) AND (INREGISTER)
#7 (#1 and #2) AND (INREGISTER)
#8 (#3 or #4 or #5 or #6) AND (INREGISTER)
#9 (#7 and #8) AND (INREGISTER)
A previous search was conducted in June 2011 using the Procite software and the search strategies below:
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (cytodiagnosis or cytophotometry or “brush biops*” or “oral cdx” or oralcdx or “modified liquid
based cytology” or “exfoliat* cytolog*” or “tolonium chloride” or “toludine b*” or “toluidine b*” or tblue or t-blue or “toludine dye*”
or “toludine rins*” or “toludine stain*” or “toludine wash*” or “toluidine dye*” or “toluidine rins*” or “toluidine stain*” or “toluidine
wash*” or luminescence or fluorescen* or “light emitting diode*”))
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (“blue spectrum” or LED or luminous or “visual* adjunct*” or vizilite or microlux* or orascoptic
or velscope or lumenoscope* or autofluorescen* or chemilumiescen* or spectrophotometr* or “acetic acid” or acetowhite or “tumor
marker*” or “tumour marker*” or “neoplas* marker*”))
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (diagno* and (blood or saliva) and (analys* or inspect* or test* or examin*)))
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (diagnos* AND (exam* or histolog* or check or inspect* or screen*)))
MEDLINE via OVID search strategy
1. exp Mouth/
2. Cheek/
3. or/1-2
4. exp Carcinoma, squamous cell/di
5. exp Precancerous conditions/di
6. (tumor$ or tumour$ or cancer$ or carcinoma$ or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or
ulcer$).tw,ot.
7. (pre-cancer$ or precancer$ or premalignan$ or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2
keratosis) or candidiasis or erythroplakia or erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkeratos$).tw,ot.
8. or/4-7
9. 3 and 8
10. exp Mouth neoplasms/di
11. Lichen Planus, Oral/di
12. Oral submucous fibrosis/di
13. Oral candidiasis/di
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14. ((oral$ or mouth$ or bucca$ or “oral cavit$” or (oral adj mucosa$) or (mouth adj mucosa$) or lip or lips or tongue$ or gingiv$
or palat$ or cheek$ or “intra oral$” or intraoral$ or gum or gums or labial$) adj3 (tumor$ or tumour$ or cancer$ or carcinoma$
or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or ulcer$ or pre-cancer$ or precancer$ or premalignan$
or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2 keratosis) or candidiasis or erythroplakia or
erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkerato$)).tw,ot.
15. or/10-14
16. 9 or 15
17. Cytodiagnosis/
18. Cytological techniques/
19. Cytophotometry/
20. (brush adj3 biops$).tw,ot.
21. (“oral cdx” or oralcdx).tw,ot.
22. (“modified liquid based cytology” or (exfoliat$ adj3 cytolog$)).tw,ot.
23. (brush$ and (cytodiagnosis or cytopathology)).tw,ot.
24. Tolonium chloride/du
25. Coloring agents/du
26. (“tolonium chloride” or “tolu?dine blue” or “tolu?dine b” or tblue or t-blue).tw,ot.
27. (tolu?dine adj6 (dye$ or rins$ or stain$ or wash$)).tw,ot.
28. exp Luminescence/du
29. Fluorescence/
30. Spectrometry, fluorescence/
31. exp Luminescent Agents/du
32. Light/du
33. Tomography, Optical Coherence/
34. (visual$ adj5 (“light emitting diode” or “blue spectrum” or LED or luminous$)).tw,ot.
35. (visuali?ation adj3 adjunct$).tw,ot.
36. (vizilite or microlux$ or orascoptic or velscope).tw,ot.
37. lumenoscop$.tw,ot.
38. ((tumor$ or tumour$ or cancer$ or carcinoma$ or neoplas$ or carcinogen$ or malignan$ or metata$ or lesion$ or ulcer$) adj5
(fluorescen$ or autofluorescen$ or luminescen$ or chemiluminescen$)).tw,ot.
39. (tissue adj3 reflect$).tw,ot.
40. Spectrophotometry/
41. Acetic acid/du
42. (acetic acid adj3 (wash$ or rins$)).tw,ot.
43. acetowhite.tw,ot.
44. Saliva/an, ch
45. Tumor Markers, Biological/an
46. ((“tumo?r marker$” or “neoplas$ marker$”) adj3 (blood or saliva)).tw,ot.
47. ((analy$ or screen$ or test$ or examin$) adj3 (blood or saliva)).tw,ot.
48. Diagnosis, Oral/
49. Mass screening/
50. Physical examination/
51. ((oral$ or mouth$) adj5 (exam$ or histolog$ or check$ or inspect$)).tw,ot.
52. (visual$ adj3 (exam$ or inspect$ or screen$)).tw,ot.
53. or/17-52
54. 16 and 53
EMBASE via OVID search strategy
1. exp Mouth/
2. Cheek/
3. or/1-2
4. exp Squamous cell carcinoma/di
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5. exp Precancer/di
6. (tumor$ or tumour$ or cancer$ or carcinoma$ or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or
ulcer$).tw,ot.
7. (pre-cancer$ or precancer$ or premalignan$ or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2
keratosis) or candidiasis or erythroplakia or erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkeratos$).tw,ot.
8. or/4-7
9. 3 and 8
10. exp Mouth tumor/di
11. Lichen planus/di
12. Thrush/di
13. ((oral$ or mouth$ or bucca$ or “oral cavit$” or (oral adj mucosa$) or (mouth adj mucosa$) or lip or lips or tongue$ or gingiv$
or palat$ or cheek$ or “intra oral$” or intraoral$ or gum or gums or labial$) adj3 (tumor$ or tumour$ or cancer$ or carcinoma$
or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or ulcer$ or pre-cancer$ or precancer$ or premalignan$
or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2 keratosis) or candidiasis or erythroplakia or
erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkerato$)).tw,ot.
14. or/10-13
15. 9 or 14
16. Cancer cytodiagnosis/
17. Cytophotometry/
18. (brush adj3 biops$).tw,ot.
19. (“oral cdx” or oralcdx).tw,ot.
20. (“modified liquid based cytology” or (exfoliat$ adj3 cytolog$)).tw,ot.
21. (brush$ and (cytodiagnosis or cytopathology)).tw,ot.
22. Tolonium chloride/
23. Coloring agent/
24. (“tolonium chloride” or “tolu?dine blue” or “tolu?dine b” or tblue or t-blue).tw,ot.
25. (tolu?dine adj6 (dye$ or rins$ or stain$ or wash$)).tw,ot.
26. exp Luminescence/
27. Fluorescence/
28. Spectrofluorometry/
29. exp Luminescent Agents/
30. Light/
31. Tomography, Optical Coherence/
32. (visual$ adj5 (“light emitting diode” or “blue spectrum” or LED or luminous$)).tw,ot.
33. (visuali?ation adj3 adjunct$).tw,ot.
34. (vizilite or microlux$ or orascoptic or velscope).tw,ot.
35. lumenoscop$.tw,ot.
36. ((tumor$ or tumour$ or cancer$ or carcinoma$ or neoplas$ or carcinogen$ or malignan$ or metata$ or lesion$ or ulcer$) adj5
(fluorescen$ or autofluorescen$ or luminescen$ or chemiluminescen$)).tw,ot.
37. (tissue adj3 reflect$).tw,ot.
38. Spectrophotometry/
39. Acetic acid/
40. (acetic acid adj3 (wash$ or rins$)).tw,ot.
41. acetowhite.tw,ot.
42. Saliva/
43. Tumor Marker/
44. ((“tumo?r marker$” or “neoplas$ marker$”) adj3 (blood or saliva)).tw,ot.
45. ((analy$ or screen$ or test$ or examin$) adj3 (blood or saliva)).tw,ot.
46. Mass screening/
47. Physical examination/
48. ((oral$ or mouth$) adj5 (diagnos$ or exam$ or histolog$ or check$ or inspect$)).tw,ot.
49. (visual$ adj3 (exam$ or inspect$ or screen$)).tw,ot.
50. or/16-49
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51. 15 and 50
MEDION search strategy
Searched using the code C (malignancies), and screened the results for oral cancer terms.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have included mouth self examination as an additional index test in this review.
We have removed the index test training and calibration signalling question from theQUADAS -2 assessment of methodological quality.
The diversity of index tests meant we were unable to uniformly apply this criterion to all the studies. For example for the conventional
oral examination, the index test was conducted by a variety of personnel of differing clinical experience. Where we would expect that,
for example basic health workers would need specific training and the adequacy of the training would be evaluated, the same cannot
be said for experienced general dental practitioners or oral specialists. The challenge is even greater when considering different index
tests; for example training and calibration of mouth self examination. For all index tests, we would expect that any training given would
be reported and any diagnostic criteria followed in the index test assessment would have been piloted/validated. All study information
pertaining to how the index test was carried out and interpreted is detailed in the Characteristics of included studies tables.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Health Status; Early Detection of Cancer [methods; ∗standards]; Lip Neoplasms [diagnosis]; Mouth Neoplasms [∗diagnosis]; Ran-
domized Controlled Trials as Topic; Sensitivity and Specificity
MeSH check words
Adult; Humans
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